

AUTHOR INDEX

- Abo, Toru, 1931
Akeson, Richard, 1995
Alexander, Michael A., 2243
- Babiuk, Lorne A., 1957
Bach, Fritz H., 1944
Bancewicz, John, 2020
Barr, Ronald, 1977
Benacerraf, Baruj, 2073
Benjamin, D. C., 2125
Bernhardt, Gregory, 2295
Biddison, William E., 2243
Bloom, Barry R., 2094, 2103
Bokisch, Viktor A., 2145
Bonnard, Guy D., 2058
Bridges, Sandra H., 2206
Briles, David E., 2161
Brosnan, Celia Fildes, 2094, 2103
Butterworth, Anthony E., 2221, 2230
- Carlson, George A., 2130
Carpenter, Charles B., 2020
Charoensiri, Surin, 2291
Cicurel, Lucienne, 1951
Cohen, Philip L., 2034
Cooper, Max D., 2067
Cooper, Neil R., 2047
Cowan, Elliot P., 2243
Croce, Carlo M., 1951
Cullen, Susan E., 2083
Curtiss, Linda K., 1966
- David, John R., 2078, 2221, 2230
David, Peter H., 2221, 2230
Davie, Joseph M., 1987, 2161
Debré, Patrice, 2073
Diener, E., 2199
Dierich, Manfred P., 2145
di Mayorca, Giampiero, 2295
Dray, Sheldon, 2295
Dunnick, Wesley A., 1944
Dutton, Richard W., 2262
- Edgington, Thomas S., 1966
Ellner, Jerrold J., 2034, 2053
Ennis, Francis A., 2167
- Fauci, Anthony S., 2281
Feldman, Joseph D., 2269
Førre, Øystein, 2275
Franks, David, 2230
Frikke, Maureen J., 2206
- Gershon, Richard K., 2117
Glovsky, M. Michael, 2182
Goers, John W., 2182
Goldberg, Erwin, 2293
Goldschneider, Irving, 2040
Goyert, Sanna M., 2138
Green, Jon A., 1936
- Habu, Sonoki, 2067
Hallgren, H. M., 2004
Handa, Kazuko, 1931
Harvey, Johanne M., 2151
Haynes, Barton F., 2281
Herberman, Ronald B., 2058
Houba, Vaclav, 2221, 2230
Hugli, Tony E., 2138
- Insel, Richard A., 2009
Ishizaka, Kimishige, 1982
Ishizaka, Teruko, 1982
Israel, Evelyn, 2237
- Jennette, J. Charles, 2269
- Kane, A., 2254
Kane, Judith A., 2155
Karakawa, Walter W., 2155
Katon, Arthur K., 2291
Kay, H. David, 2058
Kelly, James P., 2213
Kikutani, Hitoshi, 2027
Kishimoto, Tadimitsu, 2026
Klinman, Norman R., 2111
Kumagai, Katsuo, 1931
- Levy, Hilton B., 1936
Lippman, Marc, 1977
Lipsky, Peter E., 2053
Lynch, Richard G., 2206
- Major, Eugene O., 2295
Man, Doreen, 2192
Manson, Lionel A., 2243
Marsh, James A., 2293
Mednis, Alma, 2015
Mehta, P. D., 2254
Meltzer, Monte S., 2176
Merler, Ezio, 2009
Metcalf, Eleanor S., 2111
Michaelsen, Terje E., 2275
Minta, Joe O., 2192
Mitchell, Malcolm S., 2117
Mokyr, Morgalit Birnbaum, 2117
Molinaro, Giuseppe A., 2295
Movat, Henry Z., 2192
Mukkur, T. K. S., 1957
- Natvig, Jacob B., 2275
Nishizawa, Yoshio, 2027
- O'Hara, Donald S., 1971
Owen, John J. T., 2067
- Palmer, Jon C., 2243
Pape, Gerd R., 1919, 1925
Paradysz, Jean M., 2020
Parker, Charles W., 2213
Paterson, Philip Y., 2151
Pavan, Peter Reed, 2167
- Perlmann, Peter, 1919, 1925
Perlmutter, Roger M., 2161
Piessens, Willy F., 2078
Pressman, David, 1962
- Raff, Martin C., 2067
Rao, V. Srinivasa, 2117
Remold, Heinz G., 2015, 2078, 2221, 2230
Riblet, Roy, 2088
Rosenthal, Alan S., 2053
Rouse, Barry T., 1957
Rubinstein, S., 2199
- Sachs, David H., 2083
Schroer, Joyce, 1987
Schumaker, Verne N., 2182
Seeger, Robert C., 1995
Seon, Ben K., 1962
Shevach, Ethan M., 2034
Shimizu, Yoshinobu, 1931
Shinohara, Nobukata, 2083
Shiozawa, C., 2199
Singh, B., 2199
Skubitz, Keith M., 1971
Smith, Thomas W., 1971
Spiegelberg, Hans L., 2138
Stevenson, Mary M., 2176
Stoner, Gerald L., 2094, 2103
Strom, Terry B., 2020
Sturrock, Robert F., 2221, 2230
Swain, Susan L., 2262
- Taylor, Benjamin A., 2088
Theze, Jacques, 2073
Thormar, H., 2254
Tilney, Nicholas L., 2020
Troye, Marita, 1919, 1925
- Urban, Joseph F., Jr., 1982
- Wainberg, Mark A., 2237
Waltenbaugh, Carl, 2073
Wardley, Richard C., 1957
Watson, James, 2088
Webster, Leslie T., Jr., 2151
Wedner, H. James, 2213
Wegmann, Thomas G., 2130
Weinbaum, Frederic I., 2288
Weintraub, Jonathan, 2288
West, William H., 2058
Wheat, Thomas E., 2293
Williams, Juliann, 1936
Wisniewski, Henryk M., 2094, 2103
Wright, Donald E., 2067
- Yamaguchi, Tai, 1931
Yamamura, Yuichi, 2027
Yunis, E. J., 2004
- Ziccardi, Robert J., 2047, 2182

*The Editorial Staff of The Journal of Immunology is grateful to the many ad hoc reviewers who served The Journal and its contributors.
We acknowledge our appreciation for their efforts.*

N. F. Adkinson	J. J. Cohen	G. Goldstein	S. Leskowitz
W. Adler	Z. A. Cohen	E. S. Golub	B. B. Levine
A. Ahmed	R. Cone	N. Gonatas	D. Levy
C. Alper	M. D. Cooper	D. Goodman	J. A. Levy
D. B. Amos	N. R. Cooper	A. A. Gottlieb	M. Lichtman
P. Anderson	S. R. Cooperband	C. H. Granatik	J. Lightbody
G. Andres	N. Cremer	G. A. Granger	F. Lilly
B. F. Anthony	A. Crowle	J. A. Grant	J. Lindstrom
B. G. Arnason	R. Crystal	M. F. Greaves	W. D. Linscott
R. Arnon	B. A. Cunningham	S. Green	G. W. Litman
G. L. Asherson	C. A. Daniels	H. M. Grey	T. Y. Liu
R. A. Asofsky	J. M. Darrel	D. Grove	A. F. Lo Buglio
R. Auerbach	J. David	F. C. Grumet	D. L. Lodmell
J. T. August	D. H. DeHeer	R. Guttman	Z. J. Lucas
S. Avrameas	C. DeLisi	S. Hakomori	G. B. Mackaness
J. F. Bach	B. C. Del Villano	R. Hamburger	T. Makinodan
M. K. Bach	G. Dennert	U. Hammerling	D. L. Mann
D. Baltimore	P. Dent	R. Handschumacher	J. J. Marchalonis
W. H. Bancroft	D. Despommier	M. G. Hanna	D. Marshak
M. Barile	E. Diener	T. H. Hansen	M. M. Mayer
E. V. Barnett	J. Y. Djeu	J. Hardman	E. Mays
R. Basch	P. Doherty	G. Haughton	R. McCluskey
A. Basten	G. Dorval	P. Henkart	H. M. McConnell
J. Baxter	R. Dourmashkin	M. S. Hirsch	J. R. McGhee
E. Beachey	P. Duesberg	R. Hirschhorn	D. D. McGregor
M. Bean	H. G. Durkin	R. J. Hodes	K. R. McIntire
E. L. Becker	R. Dutton	R. Hoff	C. F. McKhann
A. E. Beer	H. F. Dvorak	H. T. Holden	K. L. Melmon
G. I. Bell	J. Dwyer	P. V. Holland	T. C. Merigan
J. Bellanti	D. Edelson	F. B. Hollinger	D. Metcalf
D. Benjamin	T. S. Edgington	E. C. Holmes	R. S. Metzgar
J. E. Bennett	M. Edidin	L. E. Hood	R. L. Meyers
M. Bennett	A. Z. Eisen	R. Hunter	S. D. Miller
R. D. Berlin	E. E. Emeson	C. Isersky-Carter	G. Möller
J. A. Berzofsky	L. Epstein	T. Ishizaka	P. T. Mora
M. Bevan	M. Essex	D. Jacobs	D. C. Morrison
P. Biberfeld	S. Fairchild	C. A. Janeway	J. W. Moulder
P. Black	A. S. Fauci	J. Jones	M. Muller
R. Blanden	J. C. Feeley	E. A. Kabat	D. Murphy
H. Blomgren	A. Fefer	B. Kaltreider	A. J. Nahmias
B. R. Bloom	S. Ferrone	A. P. Kaplan	D. Nayak
E. Bloom	I. J. Fidler	M. L. Karnovsky	J. R. Neefe, Jr.
M. E. Bloom	M. Fink	D. L. Kasper	D. S. Nelson
F. J. Bollum	W. Fishman	S. E. Katz	F. A. Neva
D. Bolognesi	S. Fong	S. I. Katz	J. E. Niederhuber
B. Bonavida	W. Ford	R. S. Kerbel	A. Nisonoff
G. D. Bonnard	J. Forman	R. F. Kibler	E. Norrby
T. Borsos	E. Fox	M. Kies	R. North
H. R. Bourne	R. Freter	P. Kincade	A. Notkins
J. Braatz	H. Friedman	S. Kinsky	M. S. O'Dorisio
P. Brandtzaeg	A. Froese	C. Kirkpatrick	J. R. Oehler
A. I. Braude	S. Fuchs	W. H. Kirsten	P. L. Ogra
S. W. Brostoff	S. Galant	N. Klinman	S. H. Ohanian
D. R. Burger	J. Galen	P. Kohler	R. P. Orange
W. J. Byrd	R. Geha	W. Kolb	Z. Ovary
T. Carey	P. Gerber	S. J. Kraus	V. Paetkau
C. W. Carpenter	H. Gewurz	A. Kulczycki	R. H. Painter
J-C. Cerottini	I. Gigli	D. Lagunoff	R. Parkman
W. Ceylewski	T. J. Gill	R. N. Lausch	M. Parmely
B. Chesebro	E. Gillespie	L. Law	P. Y. Paterson
L. Chess	G. G. Gleich	H. S. Lawrence	B. Pernis
J. M. Chiller	G. G. Glenner	A. R. Lawton	S. M. Phillips
F. Chisari	G. C. Godman	S. Leddy	W. F. Piessens
W. H. Churchill	E. J. Goetzel	V. A. Lennon	J. Pincus
H. J. Cohen	A. L. Goldstein	E. Leonard	D. Pisetsky

J. M. D. Plate	G. H. Sato	D. J. Sprent	B. Waksman
M. Plaut	J. Schachter	M. F. Stanton	T. A. Waldmann
S. Pollack	M. D. Scharff	A. B. Stavitsky	R. Walford
M. J. Polley	D. J. Schendel	D. Stechschulte	D. F. W. Wallach
G. Poste	I. Scher	L. Steiner	F. E. Ward
M. Potter	G. Schiffman	J. G. Stevens	N. L. Warner
M. Poulík	J. Schlom	B. D. Stollar	J. Watson
M. D. Prager	S. Schlossman	D. Stollar	R. G. Webster
T. G. Pretlow	G. Schoolnik	T. Stossel	R. L. Weiden
A. M. Prince	J. Schrader	S. Strober	W. O. Weigle
M. R. Proffitt	R. E. Schrohenloher	J. Strominger	D. Weiss
R. H. Purcell	P. H. Schur	G. Sundharadas	M. E. Weksler
P. Quie	R. H. Schwartz	J. Swanson	R. Welsh
F. Quimby	R. C. Seeger	B. Switzer	W. West
M. Rabinovitch	D. Segre	R. C. Talamo	H. W. Wilkinson
P. Ralph	K. W. Sell	D. W. Talmage	R. C. Williams
W. E. Rawls	E. E. Sercarz	E. M. Tan	C. Wilson
R. Reisfeld	J. L. Sever	R. N. Taub	D. Wilson
E. Remold-O'Donnell	G. A. Shellam	M. A. Taubman	R. J. Winchester
E. Ribí	E. M. Shevach	F. B. Taylor	H. J. Winn
R. Rich	H. S. Shin	A. Theofilopoulos	C. Wira
C. Robb	K. Shortman	D. Thomas	I. Witz
R. B. Roberts	F. Siegal	J. S. Thompson	P. Wright
R. Rockland	M. M. Sigel	J. E. Till	K. D. Wuepper
R. Rodbard	W. K. Silvers	C-C Ting	S. Yachnin
R. Rodewald	S. C. Silverstein	T. B. Tomasi	T. Yoshida
J. C. Rogers	R. L. Simmons	G. Tomkins	M. Zatz
B. Roger-Zismann	R. P. Siraganian	N. Trainin	J. Zigelboim
W. Rosenau	G. W. Siskind	P. Trefts	T. Zimmerman
D. L. Rosenstreich	R. G. Skarnes	G. Trinchieri	R. M. Zinkernagel
D. Rowley	S. R. Smithers	J. Turk	C. M. Zmijewski
J. A. Rudbach	R. Snyderman	J. A. Van Boxel	S. Zolla
S. Russell	A. Solomon	I. van de Rijn	D. Zucker-Franklin
S. B. Salvin	P. M. Sondel	J. Vaughan	A. Zuckerman
A. Sandberg	G. Sorenson	R. Veltri	
C. J. Sanderson	P. G. Spear	F. von Lichtenberg	

AUTHOR INDEX TO VOLUME 118

- Aaronson, Stuart A., 662
Abelson, Leslie D., 943
Abo, Toru, 1931
Abplanalp, Hans A., 401
Adachi, Toshihiro, 211
Ades, Edwin W., 567
Adkinson, N. Franklin, 1317
Adler, William H., 1366
Aharonov, Aharon, 17
Ahmed, Aftab, 1143, 1499
Akeson, Richard, 1995
Alexander, Michael A., 2243
Allison, J. P., 1004
Alving, Carl R., 342
Amos, D. Bernard, 1659
Amsbaugh, Diana F., 952
Anders, Robin F., 229
Anderson, Clark L., 819
Anderson, Robert E., 1191
Anderson, Ronald, 1690
Andersson, Torbjörn, 1132
Andrews, Judith M., 466
Anger, Edward, 1095
Apte, Ron N., 1435
Arend, William P., 388, 395
Arrian, Shelley, 702
Ashman, Robert B., 729
Ashman, Robert F., 1872
Askenase, Philip W., 159, 1063, 1665
Asofsky, Richard, 574, 1335, 1612, 1682
Assimeh, Seth N., 1032
Astle, Clinton M., 1223
Atkinson, John P., 1292
Austen, K. Frank, 103, 667, 1201
Autry, Johnna R., 1191
- Baba, Toru, 762
Babiuk, Lorne A., 618, 1957
Bach, Fritz H., 1944
Badger, Alison M., 1228
Baechtel, F. Samuel, 175
Baker, Carol J., 673
Baker, Patricia J., 198
Baker, Phillip J., 952
Baltimore, Robert S., 673
Bancewicz, John, 2020
Bankert, Richard B., 1265
Barr, Ronald, 1977
Bartels, Peter H., 1191
Basham, T. Y., 863
Baughn, Robert E., 109, 1827
Becker, Elmer L., 1354
Behling, Ulrich H., 1905
Bell, C. Elliott, Jr., 826
Beller, David S., 1780
Bellone, Clifford J., 1311
Benacerraf, Baruj, 1795, 2073
Benedict, Albert A., 401
Benjamin, D. C., 2125
Benjamini, Eli, 685
Bennett, J. Claude, 67
Bennett, Robert M., 694
Ben-Sasson, Shlomo Z., 1748
Ben-Yaakov, Miriam, 600
- Berke, Gideon, 986
Bernhardt, Gregory, 2295
Bernstein, Irwin D., 122, 1090
Berry, David, 1530
Bevan, Michael J., 1370
Beverky, Peter C. L., 1739
Bhan, Atul K., 589
Bhown, Ajit S., 67
Biddison, William E., 2243
Bing, D. H., 1722
Bing, David H., 466
Bitter-Suermann, Dieter, 1822
Blaese, R. M., 881
Bloom, Barry R., 2094, 2103
Blumenthal, Robert, 129
Blyden, G., 1631
Bodmer, Barbara, 1086
Bokisch, Viktor A., 2145
Boldt, David H., 1495
Bolton, Ronald W., 1154
Bonnard, Guy D., 355, 2058
Bonventre, Peter F., 1827
Borella, Luis, 309
Borsos, Tibor, 1622, 1626
Bourne, John, 461
Boyle, Michael D. P., 1622, 1626
Brackertz, Dieter, 1639, 1645
Bradac, James, 248
Brade, Volker, 1822
Breckenridge, R. T., 12
Bridges, Sandra H., 2206
Briles, David E., 2161
Brosnan, Celia Felides, 2094, 2103
Brown, J. Lynne, 98
Brown, John Clifford, 775
Brunda, Michael J., 874
Budkowska, Agata, 1300
Buhler, Karen, 218
Bundy, Bonita M., 943
Burakoff, Steven J., 1795
Burckhardt, Johann J., 1460
Burger, Dennis R., 636
Burritt, Mary F., 723
Burton, Robert C., 971
Butterworth, Anthony E., 2221, 2230
- Caldwell, Harlan D., 437, 442
Callahan, G. N., 1004
Calvanico, Nickolas J., 455, 723
Campbell, Pamela S., 1181
Cannon, Grace B., 355
Carlo, J. R., 869
Carlson, George A., 2130
Carpenter, Charles B., 2020
Carson, Dennis A., 270
Carter, Brian G., 749
Casper, James T., 309
Cathcart, Edgar S., 947
Chan, Eva L., 1391
Chang, Tong-Hsuan, 000
Chanock, Robert M., 1275
Chaplin, Hugh, Jr., 1292
Chapuis, Rose Marie, 775
- Charoensiri, Surin, 2291
Chen, David H., 1322
Chibbaro, Anthony, 1095
Chien, Chau-Chun, 1896
Chiller, Jacques M., 274
Chiorazzi, Nicholas, 48
Chisari, Francis V., 1138
Chism, Stanley E., 971
Cho, H. J., 1249
Chorpenning, Frank W., 1154
Chu, Lily, 1252
Cicurel, Lucienne, 1951
Claesson, Morgens H., 1208
Clagett, James, 1466
Clark, Richard A. F., 13
Claus, D. R., 83
Cline, Martin J., 187
Coffman, Robert L., 1806
Cohen, Edith F., 1090
Cohen, Edward P., 903
Cohen, Philip L., 2034
Cohn, Melvin, 1806
Coligan, John E., 6
Collavo, D., 1232
Colten, Harvey R., 540, 1903
Colvin, Robert B., 1549
Conrad, Dan H., 749
Conroy, Mary Carol, 1317
Cooper, Max D., 2067
Cooper, Neil R., 2047
Cooperband, Sidney R., 1228
Cory, Michael, 466
Cotran, Ramzi S., 529
Cowan, Elliot P., 2243
Crawford, Timothy B., 1249
Croce, Carlo M., 1951
Cullen, Susan E., 1271, 1403, 2083
Curtiss, Linda K., 648, 1966
Czerski, Przemyslaw, 1499
- Dailey, Morris D., 957, 963
Daniele, Robert P., 1763, 1768
Daniels, Jerry C., 418
Dauphinée, M., 446
Daves, G. Doyle Jr., 636
David, John R., 418, 2078, 2221, 2230
David, Peter H., 2221, 2230
Davie, Joseph M., 769, 1987, 2161
Davies, S., 1232
Debré, Patrice, 2073
DeHeer, David H., 648, 1858
Delfraissy, Jean-François, 630
Derose, Joseph, 1816
Diaz, Luis A., 455
DiConza, Joseph J., 594
Diener, E., 2199
Dierich, Manfred P., 2145
Diggs, Carter L., 472
diMayorca, Giampiero, 2295
diNatale, Paola, 1016
Dixon, Frank J., 1428
Donnelly, Judith, 1239
Dorf, Martin E., 1143, 1816
Dormont, Jean, 630

- Dosch, Hans-Michael, 302
 Doubleday, John W., 1223
 Douglas, R. Gordon, 28
 Dray, Sheldon, 1397, 1580, 2295
 Dreyer, David L., 636
 Drysdale, B-E., 498
 Duncan, William R., 832
 Dunnick, Wesley A., 1944
 Dupont, Bo, 858
 Dupuy, J. M., 1219
 Dutton, Richard W., 1600, 2262
 Dvorak, Ann, 1564
 Dvorak, Harold F., 1549, 1558
 Dwyer, John M., 1665
- Eardley, Diane D., 1306
 Edelman, Robert, 62
 Edgington, Thomas S., 648, 1138, 1858, 1966
 Ehrnst, Anneka C., 533
 Eilat, Dan, 1016
 Eisenberg, Robert A., 1428
 Elboim, Charles M., 1042
 Elkins, William L., 998
 Ellner, Jerrold J., 2034, 2053
 Engel, David, 1466
 Ennis, Francis A., 2167
 Epstein, Suzanne L., 935
 Erickson, Caroline, 685
- Falkoff, Reuben Maverick, 1600
 Farrar, John J., 1129
 Fathman, C. G., 1232
 Fauci, Anthony S., 146, 1150, 1728, 2281
 Feeney, Ann J., 1488
 Feldman, Joseph D., 2269
 Feldmann, Marc, 1739
 Felsburg, Peter J., 62
 Ferguson, Ronald, 1472
 Ferrone, S., 264, 1004, 1036
 Fidler, John M., 1076
 Fink, S., 1722
 Finkelstein, Richard A., 1655
 Fireman, Philip, 334
 Fitch, Frank W., 35
 Fong, Sherman, 685
 Forman, James, 797, 803, 1655
 Forni, Guido, 1677
 Førre, Øystein, 1513, 2275
 Fortner, G. William, 1483
 Fox, David A., 48
 Frangione, Blas, 1113
 Frank, M. M., 869
 Franklin, Edward C., 1113
 Franks, David, 2230
 Fraser, Blair A., 6
 Freund, John G., 1143
 Friedlander, Mitchell H., 1558
 Frikke, Maureen, J., 2206
 Froese, Arnold, 749
 Frøland, Stig S., 1513
 Fuchs, Sara, 17
 Fuson, E., 1907
- Galanaud, Pierre, 630
 Gallin, J. I., 137
 Gallin, John I., 478
 Garbarino, Carol A., 1420
 Garrett, Martha Anne, 1712
 Gealy, W. James, 1138
- Geha, Orietta, 1286
 Geha, Raif S., 1286
 Gelfand, Erwin W., 302, 736
 Gelfand, M. C., 869
 Gengozian, Nazareth, 657
 Gerin, John L., 1300
 Gershon, Richard K., 159, 2117
 Gewurz, H., 83, 198
 Gibson, David M., 409
 Gillespie, G. Yancey, 1574
 Gilman-Sachs, Alice, 1580
 Glorioso, Joseph C., 114
 Glover, Annemarie, 1690
 Glovsky, M. Michael, 2182
 Goers, John W., 2182
 Gold, Jerome A., 594
 Goldberg, Erwin, 2293
 Goldblum, Randall, 270
 Goldschneider, Irving, 2040
 Goldstein, Byron, 1649
 Good, Robert A., 405, 858
 Gooding, Linda R., 920
 Goodman, Joel W., 1744
 Goodman, Michael G., 1744
 Goodwin, Jane, 1549
 Gordon, David S., 558
 Gorevic, Peter D., 1113
 Goroff, Diana K., 673
 Gorski, Andrzej J., 858
 Gottlieb, Paul D., 935
 Götze, Otto, 525
 Goyert, Sanna M., 0000
 Graff, K. S., 12
 Green, Christopher, 1311
 Green, I., 869
 Green, Ira, 1271, 1677
 Green, Jon A., 1936
 Greenberg, Robert S., 1181
 Greenwald, Mack, 1113
 Gresser, Ion, 721
 Grey, Howard M., 742, 819
 Griffin, Diane F., 1070
 Guggenheim, Bernhard, 1460
 Guirguis, Adel A., 342
 Gupta, Sudhir, 405
 Gyöngyössi, Maria I. C., 1032
- Habercorn, Marilyn, 248
 Habu, Sonoko, 2067
 Hadding, Ulrich, 1822
 Halbert, Seymour P., 667
 Hall, Robert E., 1903
 Haller, Otto, 1503
 Hallgren, H. M., 2004
 Hammerling, Ulrich, 1488
 Hammond, M. Elizabeth, 1549
 Handa, Kazuko, 1931
 Handschumacher, R. E., 1631
 Hanjan, S. N. S., 235, 242
 Hanly, W. Carey, 1397
 Hansen, Hans J., 55
 Hansen, John A., 858
 Hansen, Ted H., 1403
 Haran-Ghera, Nechama, 600, 607
 Härfast, Bengt, 1132
 Harley, E., 1049
 Harris, Nick S., 1480
 Harrison, David E., 1223
 Hart, David A., 797, 803
 Harvey, Johanne M., 2151
- Hauptfeld, Véra, 423
 Haynes, Barton F., 2281
 Haynes, J. David, 1063
 Hefti, Arthur, 1460
 Heine, Jochen W., 1366
 Henney, Christopher S., 71, 180
 Henson, Peter M., 1569
 Herberman, Ronald B., 355, 1244, 2058
 Hermodson, Mark A., 388
 Hertogs, Chanita F., 1435
 Hillman, Kathleen, 782
 Hitchcock, Margaret, 578
 Hodes, Richard J., 1886
 Hoffman, Rosemary, 1472
 Hoffmann, Michael K., 653, 1910
 Holden, Howard T., 1244
 Holzman, Robert S., 1672
 Hook, William A., 679
 Horwitz, David A., 1712
 Houba, Vaclav, 2221, 2230
 Howard, Maureen, 1076
 Howarth, John L., 1191
 Howell, David N., 1659
 Howie, Virgil M., 248
 Hsia, Shyuan, 1659
 Hugli, Tony E., 2138
 Humphreys, Robert E., 1143
 Hunninghake, Gary W., 146, 1728
 Hunter, Robert L., 957, 963
 Hurrell, John G. R., 226
 Hurwitz, Esther, 1338, 1348
 Husby, Gunnar, 229
- Igarashi, Tsuyoshi, 1697
 Ihle, James N., 928
 Imhoff, John, 1827
 Ingraham, Joseph S., 1896
 Insel, Richard A., 2009
 Isac, Ronit, 584
 Ishii, Yoshifumi, 625
 Ishizaka, Kimishige, 151, 211, 1982
 Ishizaka, Shigeaki, 1213
 Ishizaka, Teruko, 211, 1982
 Israel, Evelyn, 2237
 Iwasaki, Tatsuo, 256
- Jacobs, Diane M., 21
 Jegasothy, Brian V., 1379
 Jennette, J. Charles, 2269
 Johnson, Peter M., 1513
 Johnson, Richard T., 1070
 Johnson, Robert J., 489, 494, 498
 Jones, Tom B., 1880
 Jordon, Robert E., 455
- Kagnoff, Martin K., 992
 Kalica, Anthony R., 1275
 Kan, Patricia B., 1391
 Kane, A., 2254
 Kane, Judith A., 2155
 Kapikian, Albert Z., 1275
 Kaplan, Alan M., 1880
 Kaplan, Allen P., 137
 Kaplan, Henry J., 809
 Karakawa, Walter W., 2155
 Kasakura, Shinpei, 43
 Käser, Hans, 1083
 Kashket, Eva R., 1328
 Kasper, Dennis L., 673
 Kato, Eiji, 193

- Katoh, Arthur K., 2291
 Katz, David H., 48, 1441, 1449
 Kay, H. David, 355, 2058
 Keck, Klaus, 427
 Kelly, James P., 2213
 Kelly, Ken A., 749
 Khiraya, Raman, 1239
 Kidwai, Zeba 235, 242
 Kikuchi, Kokichi, 625
 Kikutani, Hitoshi, 2027
 Kilburn, Douglas G., 412
 Kim, Hyun W., 1275
 Kimoto, Masao, 840
 Kind, Phyllis D., 1129
 Kindt, Thomas J., 6
 Kishimoto, Tadimitsu, 840, 1697, 2026
 Klein, Jan, 423, 797
 Kline, Lois F., 362
 Klinman, Norman R., 998, 2111
 Knapp, Walter, 1010
 Knight, Katherine L., 1397
 Knox, John M., 109
 Koenig, Scott, 1910
 Kohl, Steve, 729
 Kojima, Somei, 251, 485
 Kolb, Hubert, 427
 Kolb, Jean-Pierre, 702, 1595
 Kondracki, Esteban, 381
 König, Wolfgang, 223
 Kornblith, Paul L., 1836
 Koshiha, Hirofumi, 625
 Koshland, Marian Elliott, 775
 Krakauer, Randall S., 1385
 Kränke, Martin, 1822
 Kravis, Thomas C., 1569
 Kreth, Hans W., 291, 296
 Kripke, Margaret L., 1483
 Krogsrud, R. L., 1607
 Kubo, Ralph T., 742
 Kumagai, Katsuo, 1931
 Kuo, Cho-chou, 437, 442
 Kuppers, Rudolf, C., 71
 Kurnick, James T., 742

 Laake, Knut, 1513
 Lammert, John M., 1397
 Lamon, E., 1907
 Landolfo, Santo, 1244
 Lang, Glen M., 749
 Langone, John J., 1622, 1626
 Lausch, Robert N., 208
 Law, Lloyd W., 1259
 Lawrence, H. Sherwood, 1672
 Lawton, Alexander R., III, 1682
 Leach, Sydney J., 226
 Leach, William M., 1499
 Leber, Paul D., 589
 Leddy, J. P., 12
 Leddy, John P., 6
 Lee, John C., 928
 Lee, Kwok-Choy, 1530
 Lee, Sheng-Chung, 88
 Leid, R. Wesley, Jr. 1201
 Leonard, Edward J., 815
 Leony, Calvin 1774
 Leskowitz, Sidney, 1564
 Leslie, Gerrie A., 1025
 Lespinato, Genevieve M., 1595
 Lett-Brown, Michael A., 815

 Leung, Cherry Y., 685
 Levine, Seymour, 1280
 Levy, Hilton B., 1936
 Levy, Julia G., 218, 412
 Levy-Leblond, E., 1219
 Lewis, George K., 1744
 Liang, Weitze, 903
 Lichtenstein, Laurence M., 1317
 Lichtman, Jeff, 1375
 Lieberman, Rose 1682
 Lint, Thomas F., 198
 Lippman, Marc, 1977
 Lipscomb, Mary F., 1748
 Lipsky, Peter E., 2053
 Locker, Joseph D., 694
 Loisillier, Felix, 1595
 Loos, Michael, 223
 Lopez, Carlos, 895, 1095
 Lord, Edith M., 1704
 Lucas, Samuel V., 418
 Lucas, Zoltan J., 88
 Lukic, Miodrag, 1564
 Lüscher, Ernst F., 514
 Ly, Bernt, 1513
 Lynch, Richard G., 2206

 MacDermott, Richard P., 1495
 Mackay, Ian R., 1639, 1645
 MacKenzie, Malcolm R., 1864
 Mahmoud, Adel A. F., 418
 Maino, Vernon C., 742
 Major, Eugene O., 2295
 Malakian, Artin, 1286
 Man, Doreen, 2192
 Mandell, Brian F., 1375
 Mann, Dean L., 943, 1271
 Mannick, John A., 1228
 Manning, Dean D., 1109
 Manseau, Eleanor J., 1549
 Manson, Lionel A., 2243
 Marcus, Donald M., 1415
 Margoliash, E., 1170
 Markham, Richard B., 952
 Marsh, James A., 2293
 Martenson, Russell E., 1280
 Martinez, Ruben D., 17
 Mathieson, Bonnie J., 1181
 Mayers, George L., 1265
 Mayol, Roberto, 998
 McCarty, Teresita, 1774
 McCluskey, Robert T., 589
 McGuire, Travis C., 1249
 McIntosh, Ann Tozier, 1574
 McKenzie, Ian F. C., 1739
 McMaster, Philip R. B., 1335
 McMaster, Robert, 218
 Medicus, Rudolf G., 525
 Mednis, Alma, 2015
 Medof, M. Edward, 694
 Mehra, V. L., 242
 Mehta, P.D., 2254
 Mehta, Satish, 723
 Melewicz, F. Michael, 558, 567
 Melmon, Kenneth L., 756
 Meltzer, Monte S., 77, 2176
 Merler, Ezio, 2009
 Merluzzi, Vincent J., 1228
 Metcalf, Donald, 1208
 Metcalf, Eleanor S., 2111
 Meyers, Paul, 1541

 Michael, J. Gabriel, 505
 Michael, J. Mark, 1292
 Michaelsen, Terje E., 1513, 2275
 Milgrom, Felix, 381
 Miller, Jacques F. A. P., 1639
 Miller, R. G., 1049, 1057
 Miller, Richard G., 166
 Minta, Joe O., 736, 2192
 Mishell, Robert I., 1391
 Mitchell, Graham F., 1637, 1645
 Mitchell, Malcolm S., 2117
 Miyawaki, Toshio, 193
 Mokyr, Morgalit Birnbaum, 2117
 Mole, John E., 67
 Molinaro, Guiseppe A., 2295
 Momayezi, Massoud, 427
 Monaco, Anthony P., 1456
 Morell, Andreas, 1083
 Morisawa, Seyi, 1213
 Moriya, Naoki, 193
 Morrison, David C., 21, 362, 1852
 Morse, Herbert C., III, 574, 1682
 Mortensen, Richard F., 198
 Movat, Henry Z., 2192
 Moy, Jeffrey, 1507
 Mozes, Edna, 584
 Muchmore, A. V., 881
 Mukkur, T. K. S., 1957
 Müller-Eberhard, Hans J., 525
 Musher, Daniel M., 109
 Musson, Robert A., 1354

 Nabholz, M., 1232
 Nadler, Lee M., 1886
 Nagaoki, Takeshi, 193
 Nagel, James, 000
 Nagle, R. B., 869
 Nahmias, Andre J., 729
 Namba, Yuziro, 1379
 Nash, Geoffrey S., 1495
 Nath, Indira, 235
 Nathan, Carl F., 1612
 Nathenson, Stanley G., 98
 Natvig, Jacob B., 229, 1513, 2275
 Neiders, Mirdza E., 1682
 Nelson, David L., 943
 Newby, Timothy J., 461
 Newman, Edward S., 55
 Ngan, Bo-Yee, 736
 Nicholson, Anne, 103
 Nilsson, Sten, 1271
 Nishizawa, Yoshio, 2027
 Nisonoff, Alfred, 909
 Nitecki, Danute E., 1311
 Noguchi, Sanai, 840
 Nomura, Kohji, 1280
 Nordstoga, Knut, 229
 Novogrodsky, Abraham, 852
 Nowell, Peter C., 1763, 1768
 Nowotny, Alois, 1905
 Nowowiejski, I., 446
 Nozima, Tokukiti, 256

 O'Flaherty, Joseph T., 1586
 Ogra, Pearay L., 248
 Ohanian, Sarkis H., 1626
 O'hara, Donald S., 1971
 Okada, Masaji, 1697
 Okuda, Norihiko, 193
 Oldstone, Michael B. A., 282, 316

- ole-MoiYoi, Onesmo, 667
 Oleske, James M., 729
 Olson, George B., 1191
 Oppenheim, Joost J., 77
 O'Reilly, Richard J., 895, 1095
 Osborne, David P., Jr. 1441, 1449
 Osmand, A. P., 83
 Otani, Shuzo, 1213
 Ovary, Zoltan, 251, 485
 Owen, Frances L., 909
 Owen, John J. T., 2067
 Owens, James D., 1335
- Page, Roy, 1466
 Pagieroni Teresa, 1864
 Pahwa, Savita, 858
 Painter, R. H., 1722
 Palmer, Jon C., 2243
 Pape, Gerd R., 1919, 1925
 Papoian, Ruben, 1524
 Paradysz, Jean M., 2020
 Parish, Christopher R., 612
 Parker, Charles W., 1292, 2213
 Parker, George A., 1590
 Parsons, Janey N., 1119
 Pasanen, Vilho J., 574
 Pasternack, Gary R., 489, 494, 498
 Paterson, Philip Y., 2151
 Pavan, Peter Reed, 2167
 Peled, Alpha, 600
 Pellegrino, M. A., 264, 1004, 1036
 Perelson, Alan S., 1649
 Perkins, E. H., 1607
 Perlmann, Peter, 1132, 1919, 1925
 Perlmutter, Roger M., 769, 2161
 Perrin, Luc H., 282, 316
 Persson, Ulla, 789
 Petras, K., 83
 Pfueller, Sharron L., 514
 Phillips, Don J., 567
 Phillips, R. A., 1049, 1057
 Phillips, Robert A., 166
 Phillips, S. Michael, 472, 594, 662
 Pichler, Werner J., 1010
 Pickel, Karin, 653
 Piessens, Willy F., 2078
 Plaut, Andrew, 1816
 Ploussard, John H., 248
 Pluznik, Dov H., 1435
 Polverini, Peter J., 529
 Portaro, Joe, 981
 Porter, David D., 1249
 Post, Warren, 963
 Poupon, Marie France M., 1595
 Prager, Morton D., 175
 Prange, Charles A., 1311
 Pras, Mordechai, 1113
 Prather, Suzanne O., 208
 Pratt, Karen R., 1150
 Prescott, Benjamin, 952
 Pressman, David, 1265, 1962
 Primus, F. James, 55
 Purcell, Robert H., 1275
- Qualtiere, Louis F., 1541
 Quindlen, Eugene A., 1836
- Rabson, Arthur R., 1690
 Raff, Martin C., 2067
 Raffel, Sidney, 874
- Ranken, Raymond, 1744
 Rao, V. Srinivasa, 2117
 Recht, Bernard, 775
 Reid, Willis A., 594
 Reinisch, Carol L., 1042
 Reisfeld, R. A., 264, 1004, 1036
 Remold, Heinz G., 1, 2015, 2078, 2221, 2230
 Rennick, Donna, 685
 Reynolds, Herbert Y., 323
 Riblet, Roy, 2088
 Rich, Robert R., 1252
 Rich, Susan Sollday, 1252
 Richards, Robert L., 342
 Rocklin, Ross E., 1734
 Rosen, Fred S., 466
 Rosenau, Werner, 1507
 Rosenberg, Steven A., 1590
 Rosenberg, Yvonne J., 612
 Rosenblatt, Joe, 981
 Rosenfeld, S. I., 12
 Rosenstreich, David L., 129
 Rosenthal, Alan S., 2053
 Roubinian, Jirayr R., 1524
 Rouse, Barry T., 618, 1957
 Rozmiarek, Harry, 1154
 Rubens, Robert P., 180
 Rubin, Albert L., 852
 Rubinstein, S., 2199
 Rubio, Nazario, 607
 Ruddick, John H., 1025
 Russell, Stephen W., 1574
- Sabolovic, Domagoj, 1595
 Sachs, David H., 1403, 2083
 Sadoff, Gerald C., 1843
 Safai, Bijan, 858
 Sanderson, Richard J., 1409
 Sandler, Jeffrey A., 137
 Saxon, Andrew 1872
 Schachner, Melitta, 551
 Schechter, Alan N., 1016
 Scherz, Rudolf, 1083
 Schick, Barbara, 986
 Schicker, Cornelia, 427
 Schilling, Rainer, M., 166
 Schlamowitz, Max, 782
 Schlegel, Robert A., 1076
 Schlossman, Stuart F., 544, 1042
 Schmitt-Verhulst, Anne-Marie, 330, 1420
 Schneeberger, Eveline E., 466
 Schreiber, Alan D., 1119
 Schroer, Joyce, 1987
 Schubert, Richard D., 418
 Schumaker, Verne N., 2182
 Schurko, Elizabeth, 1403
 Schwarting, Gerald A., 1415
 Schwartz, Anthony, 159
 Schwartz, Benjamin D., 1271
 Schwartz, Robert S., 1239
 Scibienski, Robert J., 685
 Seeger, Robert C., 981, 1995
 Seegmiller, J. E., 270
 Seetharam, Shakuntla, 826
 Segal, David M., 1338, 1348
 Sehon, Alec H., 749
 Sell, Kenneth W., 1143, 1499
 Sen, Luisa, 302
 Sensabaugh, George F., 1704
 Seon, Ben K., 1962
 Sercarz, Eli E., 1306
- Sereno, Mitzi M., 1275
 Shaw, Anita R., 782
 Shearer, Gene M., 756, 1420
 Sheehan, James M., 1328
 Shen, Fung-Wen, 485
 Shepperdson, Frances T., 1409
 Shevach, Ethan M., 1677, 2034
 Shih, J. Wai-kuo, 1300
 Shimizu, Yoshinobu, 1931
 Shin, Hyun S., 489, 494, 498
 Shin, M. L., 869
 Shinohara, Nobukata, 1403, 2083
 Shiozawa, C., 2199
 Sholley, Milton M., 529
 Shore, Steven L., 558, 567, 729
 Shortman, Ken, 1076
 Showell, Henry J., 1586
 Siboo, Russell, 1086
 Siegal, Frederick P., 642
 Siegal, Marta, 642
 Siegel, J., 83
 Silverberg, Shonni J., 466
 Silverman, Stuart L., 947
 Simmons, Richard L., 1472
 Simon, Philip L., 1129
 Simons, Ruth L., 28
 Simpson, Elizabeth, 756
 Simpson, Janney M., 418
 Singh, B., 2199
 Siraganian, Reuben P., 679
 Skidmore, Barry J., 274
 Skor, D., 83
 Skubitz, Keith M., 1971
 Skvaril, Frantisek, 1083
 Sletten, Knut, 229
 Sloyer, John L., Jr., 248
 Small, Myra, 1517
 Smith, Daniel J., 710
 Smith, Jerry W., 114
 Smith, John A., 226
 Smith, Thomas W., 1971
 Sonozaki, Hidekichi, 762
 Sowinski, Richard, 1280
 Speckart, Stephen F., 1495
 Spiegelberg, Hans L., 2138
 Spilberg, Isaias, 1375
 Spragg, Jocelyn, 667, 1201
 Stadecker, Miguel J., 1564
 Starr, Stuart E., 729
 Stashak, Philip W., 952
 Stashenko, Philip P., 544
 Steinberg, Alfred D., 1016
 Stejskal, Vera, 1132
 Stenzel, Kurt H., 852
 Stephenson, John R., 662
 Stevens, Ronald H., 1872
 Stevenson, Mary M., 2176
 Stites, Daniel P., 1704
 Stoner, Gerald L., 2094, 2103
 Storb, Rainer, 1799
 Straus, David, 1827
 Strauss, Phyllis R., 1328
 Streilein, J. Wayne, 809, 832
 Strober, Warren, 943, 1385
 Strom, Terry B., 2020
 Sturrock, Robert F., 2221, 2230
 Stux, Stephen V., 909
 Sukhupunyaraksa, Surintra, 694
 Svec, Dianna, 334
 Swain, Susan L., 2262

- Takatsu, Kiyoshi, 151
Takei, Fumio, 412
Talal, N., 446
Talal, Norman, 1524
Talmage, David W., 1409
Talwar, G. P., 235, 242
Taniguchi, Noboru, 193
Tarrab-Hazdai, Rebeca, 17
Tartof, David, 35
Taubman, Martin A., 710
Taylor, Benjamin A., 2088
Taylor, P. A., 1722
Tazaki, Kayoko, 762
Teh, H.-S., 1049, 1057
Teller, David C., 388
ter Meulen, Volker 291
Territo, Mary C., 187
Terry, William D., 1612
Theis, Gail A., 887
Theofilopoulos, Argyrios N., 1428
Thestrup-Pedersen, Kristian, 1665
Theze, Jacques, 2073
Thomas, David W., 1677
Thomas, E. Donnell, 1799
Thomas, Lewis, 1910
Thompson, Russell E., 323
Thomson, Philip D., 1480
Thormar, H., 2254
Tigelaar, Robert E., 1322
Tilney, Nicholas L., 2020
Ting, Chou-Chick, 1259
Tishon, Antoinette, 282
Toivanen, Auli, 431
Toivanen, Paavo, 431
Tomasi, Thomas B., Jr., 455, 723
Tomasz, Alexander, 451
Torisu, Motomichi, 762
Tramont, Edmund C., 1843
Trissl, Dorothea, 427
Troup, Gary M., 1191
Troye, Marita, 1919, 1925
Tsichlis, Philip, 1239
Tsoi, Mang-So, 1799
Tucker, Henry St. G., 1239
Tung, Kenneth S. K., 1774
Tyan, Marvin L., 846
Uhr, Jonathan W., 1748
Unanue, Emil R., 1780
Underdown, Brian J., 1816
Urban, Joseph F., Jr., 1982
Urbanski, G. J., 1170
Urso, Paul, 657
Vadas, Mathew, 1076, 1639, 1645
Vandenbark, Arthur A., 636
Van Zwieten, Matthew J., 589
Vatter, Albert E., 1409
Vetto, R. Mark, 636
Vignaux, Françoise, 721
Vitetta, Ellen S., 551, 797, 803
Voorting-Hawking, Madeliene, 505
Wainberg, Mark A., 2237
Wakeland, Edward K., 401
Waksman, Byron H., 1379
Waldmann, Thomas A., 1385
Wallon, Christine, 630
Waltenbaugh, Carl, 2073
Ward, Peter A., 1586
Wardley, Richard C., 1957
Warner, Noel L., 971
Warren, Kenneth S., 418
Watanabe, Naohiro, 251, 485
Watanabe, Takeshi, 840
Waters, Tomi, 334
Watson, James, 1103, 2088
Waxdal, M. J., 863
Waxdal, Myron, 1271
Webb, D. R., 446
Weber, Susanne, 514
Webster, Douglas E., 395
Webster, Leslie T., Jr., 418, 2151
Wedner, H. James, 2213
Weens, Joan, 1239
Wegmann, Thomas G., 2130
Weiden, Paul L., 1799
Weigle, William O., 274, 1852
Weinbaum, Frederic I., 1322, 2288
Weinstein, Yacob, 756
Weintraub, Jonathan, 2288
Weiss, Arthur, 1122
Wells, Robert A., 472
Welsh, Raynold M., Jr., 348
West, William H., 355, 2058
Wheat, Thomas E., 2293
Whitney, Richard, 218
Wiegand, Gerd, 296
Wiggzell, Hans, 1503
Wiktor-Jedrzejczak, Wieslaw, 1499
Williams, Betsy, 1466
Williams, Juliann, 1936
Wilson, Clarence, 1843
Wilson, Curtis B., 1788
Winger, Larry A., 1763, 1768
Winkelstein, Jerry A., 451
Wisniewski, Henryk M., 2094, 2103
Wong, Catherine Y., 1159, 1165
Wood, Mary L., 1456
Wood, William C., 1836
Woodbury, Max A., 1659
Woodroffe, Andrew J., 1788
Woodruff, Jack F., 1159, 1165
Woodruff, Judith J., 1159, 1165
Woody, James N., 1739
Wright, Donald E., 2067
Wright, Peter W., 1090
Wyatt, Richard G., 1275
Wyler, David J., 478
Yamaguchi, Tai, 1931
Yamamura, Yuichi, 840, 1697, 2027
Yamanaka, Norboru, 625
Yonkosky, Donna M., 947
Yuan, Dorothy, 551
Yunis, E. J., 2004
Yunis, Edmond, 1286
Yurt, Robert W., 1201
Zatz, Marion M., 330, 1181, 1348
Zeiger, Robert S., 540
Zeltzer, Paul M., 981
Ziccardi, Robert J., 2047, 2182
Zolla-Pazner, Susan, 702

SUBJECT INDEX

- Acid-catalyzed hydrolysis of J chain, 67
Actinomyces viscosus, mitogenic activity, 1435, 1460
Acute lymphoblastic leukemia, *see under* Leukemia
Acute otitis media, *see under* Otitis media
Adenosine deaminase immunoassay, 270
Adenosine monophosphate, cyclic, IgG production and, 2027
Adenylate cyclase, immunologic histamine release and, 578
Adjuvant, Freund's, conformational integrity of myoglobin in, 226
Age
 effect on mitogen-stimulated lymphocyte production of interferon, 1366
 -related T cell function changes, 1607
 -related T cell progenitor decrease, 846
 suppressor lymphocytes and, 2004
Aleutian disease viral antibody detection methods, 1249
Alloantigen
 Ala-1, T and B effector cell expression, 1488
 cellular immunity to, 832
 cytotoxic lymphocyte precursors specific to, 1057
 distribution on Fc receptor-bearing lymphocytes, 943
 humoral immunity to, 832
 -induced suppressor cells, in MLR and CML, 1886
 Ly-5 and Ly-6, expression on cytotoxic effector cells, 1739
 -stimulated thymocytes, induction of cell-mediated cytotoxicity, 1129
Alloantisera, Ia-like molecules precipitated from chronic lymphocytic leukemia cells by, 1271
Allogeneic effect
 negative, *in vitro*, 2262
 on tumor growth, 1441, 1449
Allogeneic stimulation, lymphocyte proliferation in response to, 1966
Allograft
 rejection, cellular components, 2020
 skin, cyclophosphamide effect on specific unresponsiveness to, 1456
Alloimmunization
 effect on T cells in GVH reactions *vs* allogeneic effect, 574
 -induced cytotoxicity in T cells, 1600
Allotype
 a1, production of IgM anti-para-azobenzenearsonate antibodies, 1896
 f69, 1397
 f70, 1379
 g76, 1379
 g77, 1379
 IgA, 1397
 n83 and n84 IgM, genetic control, 1580
 7S immunoglobulin, 401
Amine, vasoactive, delayed hypersensitivity and, 159
Antibody, *see also* Xenoantibody
 after RSV challenge in avian leukosis virus-infected chickens, 1541
Aleutian disease viral, detection methods, 1249
anti-DNA, specificity, 694
-antigen complexes, measles virus, 316
-antigen-mediated injury, platelet accumulation at site, 1569
anti- μ , humoral immunosuppression by, 1109
anti-phosphorylcholine, 1987
anti-streptococcal, IgM and IgG, 2161
classes, Ir gene control, 427
cross-reactive with carcinoembryonic antigen, 55
cyclic, to polyglycerophosphate, 1154
cytophilic, in experimental autoimmune myasthenia gravis, 17
-dependent cell-mediated cytotoxicity, as test for biologic activity of IgG oligomers, 1348
-dependent cell-mediated demyelination, 2103
-dependent cellular cytotoxicity, *see under* Cytotoxicity
Fab-hapten interactions, 1971
-forming cell, antigen modulation of, 1649
-forming cell line, ontogeny, 612
-forming cell response, allogeneic T cell suppression of, 2262
-hapten reaction kinetics, 1971
hemagglutination-inhibition, alternative pathway C activation, 533
hemolysin, classical pathway C activation, 533
herpes simplex plaque elimination by, 2167
IgE, 1569
 binding to, 749
 development after immunization with tetanus-diphtheria toxoids, 334
 induction in spleen cells, 840
 production, DNP-Ficoll effect on, 251
 production, suppression of, 485
IgG-hapten complex, C1 activation by, 2182
IgG1-mediated suppression of tumor growth, 489, 494, 498
IgM, anti-para-azobenzenearsonate, 1896
killing of tumor cells, Con A effect on, 1626
measles virus cytotoxic, C activation by, 533
-mediated eosinophil-mediated damage to *S. mansoni*, 2221, 2230
-mediated macrophage suppression, 2117
-mediated tumor growth suppression, 489, 494, 498
myeloma-specific, 2206
of human origin, IgM-induced cell-mediated cytotoxicity with, 1907
opsonophagocytic, to Group B streptococci, 673
reaction to paralogoside, 1415
reaginic, formation, 151
regulatory effect on pulmonary immune response to locally administered antigen, 1728
response, *see under* Response
to influenza virus infection, 256
tRNA-specific, 1016
viral
 -dependent cellular cytotoxicity, mononuclear cell in blood mediating, 558, 567
 in middle ear fluid, 248
Antigen
 A. viscosus, as B cell mitogens, 1460
 -antibody complexes, measles virus, 316
 -antibody mediated injury, platelet accumulation at site, 1569
 -antibody-mediated macrophage suppression, 2117
 antibody regulatory effect on pulmonary immune response to, 1728
 as activator of primed T lymphocytes, 2053
 B cell, immunogenicity, 1036
 -binding lymphocyte, *see under* Lymphocyte
 bullous pemphigoid, isolation, 455
 C. trachomatis
 purification, 437
 serodiagnosis of LGV with, 442
 carcinoembryonic, antibody cross-reactive with, 55
 carrageenan-treated, macrophage dependency, 1213
 cell-mediated immunity, 957, 963
 cell surface
 nervous system-specific, 551
 on papovavirus-transformed cells, 2295
 cross-reacting, in chemically induced sarcomas, 1590
 differentiation, in Schwann cell, 826
 exogenous, induced cell-mediated interstitial nephritis, 589
 hepatitis B
 core, immunochemistry and polypeptide composition, 1300
 surface, 369
 histocompatibility
 cell cooperation and, 431
 homology requirements for secondary cell-mediated lympholysis and mixed lymphocyte reactions to TNP-modified syngeneic lymphocytes, 1420
 in lysis by T cells activated to oncofetal and plasmacytoma antigens, 971
 influence on susceptibility to MLV infection, 1239
 interferon effect on expression, 721

Antigen—continued

- K and D loci products, xenogeneic cell-mediated cytotoxicity for, 1795
- major, cellular and humoral immunity to alloantigens, 832
- minor, cytotoxic response to, 1370
- non-identity, semi-syngeneic and allogeneic cell destruction as consequence of, 2130
- on TNP-modified spleen cells, 797, 803
- public specificity, genetic control of humoral response to, 1403
- restriction in cell-mediated cytotoxicity and transplantation immunity to leukemia-associated antigens, 1259
- typing, 423
- HLA**
 - biologic and chemical characterization, 1004
 - identical siblings, cellular inhibition and serum-blocking factors in patients with marrow grafts from, 1799
 - urinary, 264
- Ia**
 - Ag-B-linked analogue, 2083
 - interferon effect on expression, 721
 - like molecules from chronic lymphocytic leukemia cells, 1271
 - LPS-induced, 1103
 - of Group B Streptococcus, 0000
 - on thymocytes, 998
 - induced arthritis, 1639, 1645
 - induced changes
 - in cyclic nucleotide levels, 446
 - in splenic prostaglandin, 446
 - initiated B lymphocyte differentiation, 1076
 - leukemia-associated, transplantation immunity to, 1259
 - lipid-conjugated
 - immune response to, 957
 - interaction with macrophages and T lymphocytes, 963
 - Ly-1, expression on helper and nonspecific suppressor T cells, 485
 - modulation of antibody-forming cells, 1649
 - neural membrane, 1995
 - oncofetal, lysis by T cells activated to, 971
 - plasmacytoma, lysis by T cells activated to, 971
 - polysaccharide, of Group B Streptococcus type Ia, 2155
 - recognition in T cell killing, 71, 544
 - schistosomal, partially purified, biologic activity, 373
 - specific B cells, antigen feeding effect on, 992
 - specific T cell factors, 584, 2199
 - stimulation
 - in delayed hypersensitivity induction, 874
 - primary or secondary, co-dominance of suppression after, 1306
 - suppressed effector cells, 203
 - surface, coded for by chromosomes 7 and 17, 1951

- T cell, 625
- thymus-dependent, suppression of immune response to, 789
- tumor-associated, soluble, MIF production stimulated by, 1244
- tyr(TMA), B cell expansion to, 1311
- V_H fragment, 2275
- Antiserum**
 - against pancreas, immunologic reactivity of urokalikrein with, 667
 - homologous idiotypic, 769
 - to lymphohemopoietic precursor cells, 2040
- Antiviral defense, neutrophils in, 1957**
- Arthritis, antigen-induced, 1639, 1645**
- Ascitic tumor, cytotoxic effector cells, 2243**
- Autoantibody**
 - formation, neonatal thymectomy and splenectomy effects on, 1524
 - response, anti-X anti-erythrocyte, 1858
- Autoimmunity, anti-tumor immunity accompanied by, 175**
- Avian leukosis virus, tumor growth and antibodies after RSV challenge, 1541**
- Bacillus Calmett-Guérin**
 - cutaneous leishmaniasis experiments and, 2288
 - treated mice, nonphagocytic adherent cell from peritoneal cavity, 1612
 - tumoricidal and chemotactic responses by macrophages activated by, 2176
- Bacteria, see under Lipopolysaccharide, bacterial**
- Basophil**
 - chemotaxis to C5a, histamine-induced inhibition of, 815
 - complement-induced histamine release from, 679
 - cutaneous
 - hypersensitivity, 1549
 - response, 1063, 1564
 - IgE measurement on, 1317
- Blastogenic factor, induction of cytotoxic cells, 43**
- Blood**
 - cell, see also Erythrocyte
 - effector, in viral antibody-dependent cellular cytotoxicity, 558
 - K, in viral antibody-dependent cellular cytotoxicity, 567
 - red, plaque-forming response to, 1228
 - L lymphocytes, functional properties, 1712
 - leprosy and normal, PHA-sensitive lymphocytes, 242
- Blood, peripheral**
 - cytolytic effector cells, 1919, 1925
 - leukocytes, regulation of Ig production, 1872
 - lymphocytes
 - antibody response, 630
 - glucocorticoid receptors, 1977
 - mitogen-induced proliferation, 1763, 1768
 - mitogenic receptors on, 2213
 - mitogenic response, 193
 - stimulation by periodate, galactose oxidase, soybean agglutinin, and peanut agglutinin, 852

- subpopulations by electrophoretic mobility, 235
- monocytes, isolation and enumeration, 1409
- plaque-forming cell detection in, 1480
- studies in multiple myeloma, 1864
- Bone marrow**
 - B lymphocyte activation, 1150, 2067
 - cells, tolerance induction, 2111
 - dependent effector cells, 1503
 - grafts, from HLA identical siblings, 1799
- Bullous pemphigoid antigen, isolation, 455**
- Cancer, cytolytic effector cells in peripheral blood of patients, 1919, 1925**
- Carbohydrate hapten, streptococcal Group C, 6**
- Carcinoembryonic antigen, antibody cross-reactive with, 55**
- Carcinoma, colon, antigen-III, 55**
- Caries, dental, effect of local immunization with glucosyltransferase on, 710**
- Carrageenan, effect on immune response, 1213**
- Carrier-mediated transport, enhancement after immunologic activation of peritoneal macrophages, 1827**
- Cell, see also specific types of cells**
 - adherent nonphagocytic, of peritoneal cavity, 1612
 - allogeneic, destruction, 2130
 - antibody-forming, antigen modulation of, 1649
 - antigen, surface, nervous system-specific, 551
- B**
 - alloantigens on sIg-positive lymphocytes, 943
 - antigen-specific, 992
 - antigens, immunogenicity, 1036
 - characteristics, lymphomas with, 1181
 - defect in C3H/HeJ mice, 274
 - effector, expression of Ala-1, 1488
 - enhancing effects of irradiated T cells on, 642
 - expansion to tyr(TMA), 1311
 - maturation, 2111
 - mitogens, 662, 1460
 - proliferation effected by cross-linking T cell mitogens, 863
 - separation by column fractionation, 1919
 - tolerance to dextran B1355, 1265
 - tonsil, responses to pokeweed mitogen, 2009
 - triggering, molecular control of, 2199
 - cholera toxin-sensitized, inability to induce T cell-mediated cytotoxicity, 1655
 - colony-forming B lymphocyte, 1208
 - cooperation, histocompatibility in, 431
 - cytolytic effector, in peripheral blood, 1919, 1925
 - cytotoxic, cell proliferation and, 1090
 - cytotoxic effector
 - against myeloid cell line, 355
 - analysis in SSPE, 296

- function, corticosteroids and, 146
 in ascitic tumor, 2243
 Ly-5 and Ly-6 alloantigen expression, 1739
- effector
 antigen-suppressed, 203
 in viral antibody-dependent cellular cytotoxicity, 558
 marrow dependence, 1503
 of human origin, IgM-induced cell-mediated cytotoxicity with, 1907
 T and B, expression of Ala-1, 1488
 Fc receptor-bearing, IgG oligomer binding to, 1338
- helper, *see also* Cell, T-helper
 activity enhancement, 151
 generation of, 1379
 Ly-1 antigen expression, 485
- inflammatory, in solid neoplasms, 1574
- K
 in antibody-dependent cellular cytotoxicity, 567
 in peripheral blood of healthy and cancer patients, 1919
- killer, *see also* Cell, T, killer, 1503
- line
 antibody-forming, ontogeny, 612
 stem, normal responses from immunodeficient donors, 1223
- lymphohemopoietic precursor, antiserum to, 2040
- lytic, Con A-dependent, 180
- mast
 functional development, 211
 in antigen-antibody-mediated injury, 1569
 peritoneal, heparin release, 1201
 -mediated cytolysis, *see under* Cytolysis
 -mediated cytotoxicity, *see under* Cytotoxicity
 -mediated demyelination, 2103
 -mediated immune response, in recurrent herpes virus infections, 895, 1095
 -mediated immunity, to chemically modified antigens, 957, 963
 -mediated interstitial nephritis, 589
 -mediated lympholysis, *see under* Lympholysis
- membrane, Fc receptors, 819
- neoplastic, resistance to leukemia with injections of, 903
- neuroblastoma, neural membrane antigens on, 1995
- peritoneal
 activated, adherent, lymphocyte activation factor enhanced by, 77
 exudate, T lymphocyte requirement in local adoptive transfer by, 1774
 mast, heparin release, 1201
- plaque-forming
 assay for B lymphocyte activation in bone marrow, 1150
 detection in peripheral blood, 1480
 generation in culture, 302
 response, Con A-induced generation of suppressor cells of, 2281
- proliferation, cytotoxic cell generation and, 1090
- rosette-forming, *see under* Rosette-forming cell
- semi-syngenic, destruction, 2130
- somatic hybrids between peritoneal macrophages and SV40-transformed cells, 1951
- stimulator, macrophage as in contact sensitivity, 1677
- suppressor
 activity enhancement, 151
 alloantigen-induced, in MLR and CML, 1886
 Con A-induced generation, 2281
 culture-induced, in MLR and CML, 1886
 generation of, 1379
 in tolerance to HGG, 2125
 in tumor-bearing mice, 412
 T, 48, 653, 1665
- SV40-transformed, killing specificities by cytotoxic lymphocytes generated to, 920
- T
 age-related function changes, 1607
 age-related progenitor decrease, 846
 allogeneic, suppression of antibody-forming cell response, 2262
 antigens, 625
 -B cell cooperation, complement and, 1744
 characteristics, lymphomas with, 1181
 Con A-induced cytotoxicity, 1600
 -dependent macrophage suppression, 2117
 effect on plaque-forming response to SRBC, 1228
 effector, expression of Ala-1, 1488
 factors, antigen-specific, 584
 generation of, 1379
 -helper, B cell triggering control by, 2199
 -helper, in IgE and IgG antibody responses, 840
 -helper, in tonsil B cell responses to pokeweed mitogen, 2009
 homologous erythrocytes, 909
 in GVH reactions, 574
 irradiated, enhancing effects on B cells, 642
 killer, antigen recognition, 71
 killer, induction with 2-mercaptoethanol, 1697
 killer, lack of H-2 compatibility requirement, 971
 Ly-1 antigen expression, 485
 -mediated cytolysis, *see under* Cytolysis
 -mediated cytotoxicity, *see under* Cytotoxicity
 -mediated enhancement of syngeneic tumor growth, 1517
 mitogenic response, 193
 mitogens, cross-linking, 863
 monocyte-lymphocyte interactions, 193
 proliferation effected by cross-linking T cell mitogens, 863
 suppressor, 48, 653, 1665
- thymidine transport, 1328
- TNP-modified
 glutaraldehyde effect on, 1755
 T cell-mediated cytotoxicity against, 1755
- visceral epithelial, C receptors on, 869
- walls, pneumococcal, activation of alternative pathway, 451
- Cellular immunity, *see under* Immunity
- Cellular inhibition, in patients with marrow grafts from HLA identical siblings, 1799
- Chain
 ϵ , IgE binding to cell receptors and antibodies against, 749
 heavy
 plasma cell, 1682
 variable region, antigenic studies, 2275
 variable region, on membrane-bound Ig on chronic leukemic lymphocytes, 1513
- IgG-B₂ microglobulin complex, 1962
- J
 acid-catalyzed hydrolysis, 67
 proteolysis in polymeric Ig, 775
- light
 isoelectric focusing, 409
 spectrotypes, 2161
- Chemotaxis, basophil, to C5a, 815
- Chlamydia trachomatis* antigen
 purification, 437
 serodiagnosis of LGV with, 442
- Cholera toxin-sensitized cells, inability to induce T cell-mediated cytolysis, 1655
- Cholesterol-dependent complement activation, 342
- Chromosomes 7 and 17, coded for by surface antigens, 1951
- Colon carcinoma antigen-III, 55
- Colony-forming cell, *see under* Cell
- Colony-stimulating factor release, lymphocyte activation and, 1435
- Complement
 activation
 alternative pathway, 451, 525, 533
 by C-reactive protein-polyanion-polycation interactions, 83
 by measles virus cytotoxic antibodies, 533
 cholesterol-dependent, 342
 classical pathway, 362, 533, 723, 1622
 properdin pathway, 362
- C1
 activation by hapten-IgG antibody, 2182
 sedimentation properties, 2047
 subcomponents, 1722, 2047
- C1, DNP-HSA interaction with, 223
- Cl_s-induced vascular leakage, inhibition, 466
- C2, hemolytic assay, 736
- C2b receptor, modulation of function by cytochalasin-sensitive structures, 1292
- C3
 fragmentation, 2192
 isolation, 1032
- C4
 genetic linkage with Bf locus, 1822
 molecular size, 1903
 subunit structure, 1903
- C5 deficiency, hemostasis and platelet responses in, 12

Complement—*continued*

- C5a, basophil chemotaxis to, 815
- C567-initiated cytolysis of lymphoid cells, 198
- deficient sera, virus neutralization by, 28
- inactivation of viruses, 348
- induced histamine release from basophils, 679
- killing of tumor cells, Con A effect on, 1626
- reactive protein, *see under* Protein receptors, *see under* Receptor
- T cell-B cell cooperation and, 1744
- Concanavalin A
 - antibody response to type III pneumococcal polysaccharide effected by, 952
 - classical complement pathway and, 1622
 - cytotoxic lymphocyte precursors specific to, 1057
 - dependent lytic cells, 180
 - induced B lymphocyte activation, 2281
 - induced cytotoxicity, 1600
 - induction of cytolytic T lymphocytes, 35
 - killing of tumor cells by antibody and complement effected by, 1626
 - stimulated cells, thymidine transport, 1328
- Conglutinin assay of immune complexes, 1428
- Contact sensitivity, *see under* Sensitivity
- Cornea, delayed hypersensitivity reaction morphology, 1558
- Corticosteroid, alveolar macrophage function and, 146
- Corynebacterium parvum*-activated macrophages, functional heterogeneity, 1530
- Coxsackievirus B-3 infection, cytotoxic T lymphocytes generated during, 1159, 1165
- Cyclophosphamide
 - effect on specific unresponsiveness to skin allografts, 1456
 - induced immunosuppression in malaria, 472
 - induced splenic modifications, 1595
- Cytochalasin
 - effect on lymphocyte response to mitogen, 1472
 - sensitive structures, modulation of C2b receptor function, 1292
- Cytochrome c, antigenic structures, 1170
- Cytolysis
 - C567-initiated, of lymphoid cells, 198
 - cell-mediated, antibody-dependent, as test for biologic activity of IgG oligomers, 1348
 - lymphocyte-mediated, 71, 180
 - T cell-mediated, inability of choleragenoid-sensitized cells to induce, 1655
 - xenogeneic cell-mediated, specificity for H-2 complex K and D loci products, 1795
- Cytotoxic lymphocyte, *see under* Lymphocyte
- Cytotoxicity, *see also* Spleen cell cytotoxicity
 - alloimmunization induced, in T cells,

- 1600
- antiviral, genetic restriction, 618
- cell-mediated
 - against measles virus in SSPE, 291, 296
 - H-2 restriction, 1259
 - IgM-induced, 1907
 - induction by alloantigen-stimulated thymocytes, 1129
 - lymphocyte, 756
 - suppressor cells in, 1886
- cellular, antibody-dependent, 2058
- inhibition by protein A, 981
- to herpes simplex virus-infected cells, 729
- viral, effector cells in, 558
- viral, K cells in, 567
- cellular, mitogen-induced, in multiple myeloma, 947
- Con A-induced, in T cells, 1600
- humoral, testing, 1836
- lymphocytic
 - against myeloid cell line, 355
 - cell-mediated, 756
 - Fc receptor-bearing, 2058
 - mediated by macrophages recovered from disaggregated regressing Moloney sarcomas, 1574
- T cell-mediated, against TNP-modified cells, 1755
- to allogeneic or autochthonous tumor cells in tissue culture, 1925
- Demyelination, by activated lymphocytes in eye, 2094, 2103
- Deoxyribonucleic acid
 - anti-DNA antibodies, specificity, 694
 - purified lymphocyte subpopulation, excretion, 1495
 - synthesis, 88, 1379, 2009
- Dextran B1355, B cell tolerance to, 1265
- Dinitrochlorobenzene-induced skin inflammatory lesions, neutrophil chemotactic factor in, 762
- Dinitrophenyl
 - ϵ -L-lysine Ficoll, inhibition of leukocyte migration, 1335
 - Ficoll, tolerizing effect on IgE antibody production, 251
 - HSA, interaction with C1, 223
 - KLH, inhibition of hapten-specific leukocyte migration, 1335
- Diphtheria-tetanus toxoids, IgE antibody development after immunization with, 334
- Disaccharide hapten from streptococcal Group C, 6
- Disease, *see under* specific type of disease
- Disulfide bonding in secretory IgA, 1816
- Ear, middle, fluid, viral antibody, 248
- Electrophoretic mobility, lymphocyte subpopulation identification by, 235, 242
- Encephalitis, viral, immune response in, 1070
- Encephalomyelitis, experimental allergic active sites in myelin basic proteins, 1280

- suppression by niridazole, 2151
- Endothelial proliferation, in delayed hypersensitivity reaction, 529
- Eosinophil
 - histamine release, 540
 - mediated damage to *S. mansoni*, 2221, 2230
 - migration, histamine modulation, 137
- Erythrocyte, *see also* Blood cell
 - antibody reaction to paragloboside with, 1415
- B lymphocyte defect in anti-X anti-erythrocyte autoantibody response, 1858
- homologous, of T cells which act as aggressors in MLR, 909
- IgM-coated, receptor for, on chronic lymphatic leukemia cells, 1010
- receptor, soluble, recovery from T lymphocyte surface, 1138
- Escherichia coli* K235, LPS-mediated function modified by, 1852
- Esterase, activatable, in neutrophil immune-dependent phagocytosis, 1354
- Eye
 - anterior chamber, immune response to immunization, 809
 - demyelination by activated lymphocytes, 2094, 2103
- Factor, *see also* specific types of factor
 - Bf, genetic linkage with C4, 1822
 - chemotactic
 - inhibition of polymorphonuclear leukocyte capping, 1375
 - neutropenia induced by systemic infusion of, 1586
 - neutrophil, in DNCB-induced skin inflammatory lesions, 762
 - spleen-derived, in malaria, 478
 - helper, T cell-derived, B cell triggering control by, 2199
 - immunoregulatory, isolation from human serum, 505
 - regulatory, lymphocyte-produced, 88
 - suppressor
 - from mononuclear phagocytes, 1385
 - histamine-induced, 1734
 - T cell, antigen-specific, 584
 - transfer
 - fractionation, 636
 - specificity and structural analysis, 1944
- Fetal determinants, cross-reacting antigens in chemically induced sarcomas as, 1590
- α -Fetoprotein, lymphocytes and, 405
- Ficoll
 - DNP, tolerizing effect on antibody IgE production, 251
 - ϵ -DNP-L-lysine, inhibition of leukocyte migration, 1335
- Forssman glycolipid
 - streptococcal Group C carbohydrate hapten cross-reacting with, 6
- Gene
 - H-2, mutant, glycoprotein structure, 98
 - Ir, control of antibody class production, 427

- Genetic control
 of humoral response to H-2 public specificity, 1403
 of immune response to LDH-C₄, 2293
 of n83 and n84 IgM allotypes, 1580
 of type C RNA virus release, 662
- Genetic linkage between C4 and Bf loci, 1822
- Genetic restriction, lack of in bovine antiviral cytotoxicity, 618
- Genetics of cell-mediated lympholysis, 1286
- Gland, mammary, immune system, 461
- Globulin
 α -, immunoregulatory, immunosuppressive activity on plaque-forming response to SRBC, 1228
 anti-thymocyte, interaction with E-PHA, 2213
- Glomerulonephritis, immune complex, 1788
- Glomerulus, renal, C receptors on epithelial cells, 869
- Glucocorticoid receptors in peripheral blood lymphocytes, 1977
- Glucosyltransferase, effect of local immunization on dental caries, 710
- L-Glutamic acid⁵⁰ L-tyrosine, immunosuppression of, 2073
- Glutaraldehyde, effect on TNP-modified cells, 1755
- Glycolipid, Forssman, streptococcal Group C carbohydrate hapten cross-reacting with, 6
- Glycoprotein, mutant H-2, structure, 98
- Graft-vs-host disease, immune competence of splenic lymphocytes after, 657
- Graft-vs-host reaction
 inhibition of MOPC 315 plasmacytoma, 1441, 1449
 T cells in, 574, 653
- Granulopoiesis, LPS-induced, regulation by spleen cells, 1435
- Hapten
 -antibody reaction kinetics, 1971
 -Fab preparation interactions, 1971
 -IgG antibody complex, C1 activation by, 2182
 -IgG interactions, 1971
 -specific IgE antibody responses, 48
 -specific leukocyte migration inhibition, 1335
 -specific transfer of cutaneous basophil response, 1063
 streptococcal Group C carbohydrate, 6
- Helper cell, *see under* Cell
- Hemagglutination-inhibition antibodies, alternative pathway C activation, 533
- Hemocyanin, *see under* Keyhole limpet hemocyanin
- Hemolysin antibodies, classical pathway C activation, 533
- Hemostasis in C5 deficiency, 12
- Heparin release from peritoneal mast cells, 1201
- Hepatitis B antigen
 core, immunochemistry and polypeptide composition, 1300
 surface, 369
- Hereditary C5 deficiency, 12
- Herpes simplex plaques, antibody elimination of, 2167
- Herpes simplex virus
 antibody-dependent cytotoxicity, 729
 immune response, 114, 895, 1095
- Histamine
 -induced inhibition of basophil chemotaxis to C5a, 815
 -induced suppressor factor, effect on MIF, 1734
 modulation of eosinophil migration, 137
 neutrophil motility and, 1690
 release
 anti-IgE-induced, 1317
 from basophils, complement-induced, 679
 from eosinophils, 540
 from lung, 578
 immunologic, adenylate cyclase and, 578
- Histocompatibility antigen, *see under* Antigen
- Humoral immunity, *see under* Immunity
- Hydrolysis, acid-catalyzed, of J chain, 67
- Hypergammaglobulinemia
 immunologic tolerance, 1880
 suppressor cells in tolerance to, 2125
- Hypersensitivity, delayed
 active E rosette test, 62
 antigenic stimulation in induction, 874
 endothelial proliferation in, 529
 morphology in cornea, 1558
 restoration by lymphoid tissue, 1936
 thymus and T cell role in suppression, 1665
 vasoactive amines and, 159
- Hypogammaglobulinemia, experimental myeloma, 1385
- Immune competence of splenic lymphocytes after GVH disease, 657
- Immune complex
 conglutinin assay for, 1428
 in Moloney sarcoma-bearing rats, 2269
- Immune response, *see under* Response
- Immunity, *see also* Tumor immunity
 anti-tumor, autoimmunity and, 175
 cellular, to alloantigens, 832
 humoral, to alloantigens, 832
 tumor-specific, 971
- Immunodeficiency disease
 combined, immunoassay of adenosine deaminase in, 270
 human, 858
- Immunodeficient donors, old, normal responses in young recipients to stem cell lines from, 1223
- Immunogenicity
 of B cell antigens solubilized from cultured lymphoid cells, 1036
 of mitomycin C-treated tumor cells, 685
- Immunoglobulin, *see also* Chain
 antibody response regulated in different classes, 840
- IgA
 Fc fragment, C activation by, 723
 secretory, disulfide bonding in, 1816
- IgA- κ , SAMM 368-A plasmacytoma secreting, 1682
- IgD
 spontaneous degradation, 2138
 structure and biologic functions, 1025
- IgE
 antibody, 251, 334, 485, 749, 840, 1569
 binding to cell receptors and antibody against epsilon chain, 749
 formation after *N. brasiliensis* infection, 1982
 hapten-specific antibody responses, 48
 measurement on basophils, 1317
 synthesis in man, 334
- IgG
 antibody-hapten complex, C1 activation by, 2182
 anti-streptococcal antibodies, 2161
 -B₂ microglobulin complex, 1962
 -hapten interactions, 1971
 monocyte receptor, levamisole and, 1119
 oligomers, binding to Fc receptor-bearing cells, 1338
 oligomers, biologic activity, 1348
 production, cyclic AMP and, 2027
 -Sephadex, C1 subcomponent identification after affinity chromatography on, 1722
 soluble aggregate binding to Fc receptor, 514
 subclass measurement with heteroantiserum, 935
- IgG1, antibody, suppression of tumor growth, 489, 494, 498
- IgG2a, Fc fragments, 388, 395
- IgG2b- κ , SAMM 368-A plasmacytoma secreting, 1682
- IgM
 anti-para-azobenzenearsonate antibodies, 1896
 anti-streptococcal antibodies, 2161
 -coated erythrocytes, receptor for, 1010
 genetic control of n83 and n84 allotypes, 1580
 in humoral cytotoxicity testing, 1836
 -induced cell-mediated cytotoxicity, 1907
 secretory, 323
 measles virus-specific, 2254
 membrane-bound, on chronic leukemic lymphocytes, 1513
 polymeric, J chain proteolysis in, 775
 production regulation in peripheral blood leukocytes, 1872
- 7S, allotypes, 401
- surface
 on virgin and memory B lymphocytes, 1806
 ontogeny of cells bearing, 612
 synthesis, T cell mitogen cross-linking effect on, 863
- Immunologic reactivity of urokinase with antiserum against pancreas, 667
- Immunoregulatory factors, isolation from human serum, 505
- Immunoregulatory low density lipoprotein, 648

- Immunoregulatory properties of fractions from pregnancy urine, 881
- Immunosuppression, *see also* Response, immune
- complete humoral, 1109
 - cyclophosphamide-induced, in malaria, 472
 - IRA, on plaque-forming response to SRBC, 1228
 - leukemogenesis, cellular analysis, 600
 - niridazole-induced, urinary, 418
 - of L-glutamic acid⁵⁰ L-tyrosine, 2073
 - of T lymphocyte function by fractionated serum from tumor-bearing mice, 211
 - plasmacytoma-induced, 702
- Influenza virus, defense mechanisms against, 256
- Interferon
- antigen expression and, 721
 - defensive role against primary influenza virus infection, 256
 - production
 - by mitogen-stimulated lymphocytes, 1366
 - in Sendal virus-stimulated leukocytes, 1931
 - thymus dependence, 256
- Ionophore, lymphocyte mitogenicity and, 129
- Irradiation, whole body, effect on lymphoid tissues, 1191
- Keyhole limpet hemocyanin-DNP, inhibition of hapten-specific leukocyte migration inhibition, 1335
- Lacto-N-neotetraosyl ceramide, *see under* Paragloboside
- Leakage, vascular, C1s-induced, 466
- Leishmaniasis, cutaneous, Bacillus Calmette-Guérin and, 2288
- Leprosy, blood, PHA-sensitive lymphocytes in, 242
- Leukemia
- associated antigens, transplantation immunity to, 1259
 - lymphatic, chronic
 - IgM-coated erythrocyte receptors on, 1010
 - mitogen activation, 742
 - lymphoblastic, acute, antigenic heterogeneity, 309
 - lymphocytic, chronic, cells, Ia-like molecules from, 1271
 - resistance to, with simultaneous injections of syngeneic hybrid and parental neoplastic cells, 903
- Leukemogenic potential, immune response and, 607
- Leukemogenesis, cellular analysis of immunosuppression, 600
- Leukocyte
- culture, cytotoxic lymphocytes induced by soluble factors from, 43
 - dialysates, augmentation of lymphocyte rosette formation, 1672
 - migration inhibition, hapten-specific, 1335
 - peripheral blood, regulation of Ig production, 1872
 - polymorphonuclear, capping, inhibition by chemotactic factor, 1375
 - Sendal virus-stimulated, interferon production, 1931
- Levamisole, effect on monocyte IgG receptor, 1119
- Lipid
- A-associated protein, induction of phenotypic lymphocyte differentiation, 1910
 - conjugated antigens
 - immune response to, 957
 - interaction with macrophages and T lymphocytes, 963
- Lipopolysaccharide
- bacterial
 - complement activation by, 362
 - immunologic properties, 274
 - response to, 2088
 - E. coli* K235 modulation of function, 1852
 - immune adjuvancy, 1905
 - induced granulopoiesis, regulation by spleen cells, 1435
 - induced Ia antigen, 1103
 - induced serum factor, induction of phenotypic lymphocyte differentiation, 1910
 - induced suppression of immune response, 789
 - mitogenesis, polymyxin B inhibition of, 21
- Lipoprotein
- LDL-In, effect on lymphocyte proliferation in response to mitogen and allogeneic stimulation, 1966
 - low density, immunoregulatory, 648
- Liposomal model membrane, *see under* Membrane
- Listeria monocytogenes*, *P. acnes* effect on growth, 109
- Liver
- B lymphocyte generation, 2067
 - C-reactive protein, 1086
- Lung
- immunologic histamine release, basal adenylate cyclase and, 578
 - immunologic reactivity, 146, 1728
 - tumor, differentiation antigen expressed by, 826
- Lymphocyte, *see also* Mixed lymphocyte reaction
- activated, demyelination by in eye, 2094, 2103
 - activating factor, 1631
 - activation
 - colony-stimulating factor release and, 1435
 - in bone marrow, 1150
 - inhibition in seminal plasma, 1704
 - α -fetoprotein and, 405
 - antibody reaction to paragloboside with, 1415
 - antigen-binding, 1311
 - antigen expression, interferon effect on, 721
- B
- activation in bone marrow, 1150
 - antigen-initiated differentiation, 1076
 - colony-forming cells, 1208
 - Con A activation, 2281
 - defect in anti-X anti-erythrocyte autoantibody response, 1858
 - effect on *A. viscosus* mitogenic activity, 1435
 - functional properties, 1712
 - generation, in fetal liver and bone marrow, 2067
 - LPS-induced Ia antigen, 1103
 - migration into syngeneic tumors, 1042
 - radiosensitivity, 1191
 - surface immunoglobulins, 1806
- cytotoxic
- in measles virus infection, 282
 - induction by blastogenic factors, 43
 - killing specificities, 920
 - precursors, 1049, 1057
 - T, generation during Coxsackievirus B-3 infection, 1159, 1165
- Fc receptor-bearing
- alloantigen distribution on, 943
 - cytotoxicity of, 2058
- immune reactivity, sensitization effect on, 1379
- L, blood, functional properties, 1712
- leukemic, chronic, V_H region of membrane-bound Ig on, 1513
- macrophage interactions, 77
- Marek's disease-infected, effect on mitogen response of syngeneic spleen cells, 887
- mediated cytotoxicity, *see under* Cytotoxicity
- membrane transport, 1328
- mitogens, ionophores and, 129
- mitogen-stimulated, interferon production, 1366
- mixed lymphocyte reaction regulating subpopulations, 1252
- monocyte interactions, of T cell subpopulations, 193
- MSV-immune, MIF production from, 1244
- paramyxovirus-infected cells and, 1132
- peripheral blood
- antibody response, 630
 - glucocorticoid receptors, 1977
 - mitogen-induced proliferation, 1763, 1768
 - mitogenic receptors on, 2213
 - mitogenic response, 193
 - stimulation by periodate, galactose oxidase, soybean agglutinin, and peanut agglutinin, 852
 - subpopulations by electrophoretic mobility, 235
- phenotypic differentiation induction, 1910
- phytohemagglutinin-sensitive, in normal and leprosy blood, 242
- produced regulatory factors, 88
- proliferation, in response to mitogen and allogeneic stimulation, LDL-In effect on, 1966
- regulatory substances, 1379
- response to mitogen, 193, 1472
- rosette formation, augmentation by leukocyte dialysates, 1672
- separation by column fractionation, 1919
- splenic
- immune competence after GVH disease, 657

- reactivity against syngeneic UV-induced tumors, 1483
 subpopulation identification by electrophoretic mobility, 242
 suppressor, 2004
T
 binding to macrophages, 1748
 cytolytic, induced by Con A, 35
 cytotoxic, generation, 166, 1159, 1165
 effect on *A. viscosus* mitogenic activity, 1435
 functional properties, 1712
 in experimental allergic orchitis, 1774
 inhibitor, in tumor-bearing mice, 211
 interaction with lipid-conjugated antigen and macrophages, 963
 migration into syngeneic tumors, 1042
 PHA-activated, E rosette formation, 2291
 primed, antigen activation of, 2053
 radiosensitivity, 1191
 recovery of soluble erythrocyte receptor from, 1138
 specificity, antigen recognition, 544
 TNP-modified, H-2 homology requirements for mixed lymphocyte reaction to, 1420
 triggering, in liquid and solid cultures, 381
 Lymphocytic choriomeningitis virus, complement inactivation of, 348
 Lymphogranuloma venereum, serodiagnosis, 442
 Lymphotoxin, α -, 1507
 Lymphoid cell, *see also* Spleen cell, lymphoid
 C567-initiated cytotoxicity, 198
 immunogenicity of B cell antigens solubilized from, 1036
 Peyer's patch, 992
 tumor-associated, activity after administration of irradiated syngeneic and allogeneic tumor cells, 986
 Lymphoid proliferative response, suppression, 1122
 Lymphoid tissue
 restoration of delayed hypersensitivity, 1936
 whole body irradiation effect on, 1191
 Lympholysis, cell-mediated, 1286, 1420
 Lymphoma, *see also* Tumor cell
 AKR, F₁ resistance to, 330
 syngeneic, immune response to, 1090
 T and B cell characteristics, 1181
 virus-induced, immune response to, 122
Macrophage
 activating factor, increased responsiveness after macrophage membrane alteration, 2078
 alveolar, cytotoxic effector cell function, 146
 as stimulator cell in contact sensitivity, 1677
C. parvum-activated, functional heterogeneity, 1530
 C2b receptor function, modulation by cytochalasin-sensitive structures, 1292
 chemical modification, 1
 chemotactic responses, 2176
 dependency, of carrageenan-treated antigens, 1213
 formation, regulation by spleen cells, 1435
 function in tumor-bearing mice, 2176
 in 2-mercaptoethanol induction of killer T cells, 1697
 interaction with lipid-conjugated antigen and T lymphocytes, 963
 -lymphocyte interactions, 77, 963, 1748
 -mediated cytotoxicity, 729, 1574
 peritoneal
 carrier-mediated transport, enhancement after immunologic activation of, 1827
 SV40-transformed cells and, somatic cell hybrids between, 1951
 secretory product, thymic maturation by, 1780
 suppression, T cell-dependent, antigen-antibody-mediated, 2117
 T lymphocyte binding to, 1748
 tumoricidal responses, 2176
Malaria
 cyclophosphamide-induced immunosuppression, 472
 spleen-derived chemotactic factor, 478
 sporozoite-induced, immunity to, 1322
 Marek's disease-infected lymphocytes, effect on mitogen response of syngeneic spleen cells, 887
Marrow
 B lymphocyte activation, 1150, 2067
 cells, tolerance induction, 2111
 -dependent effector cells, 1503
 grafts from HLA identical siblings, cellular inhibition and serum-blocking factors in, 1799
 Mastocytoma, syngeneic, suppressor cells in mice bearing, 412
Measles virus
 -antibody complexes, 316
 cell-mediated cytotoxicity in, 291, 296
 cytotoxic antibodies, C activation by, 533
 cytotoxic lymphocytes, 282
 -specific immunoglobulins, 2254
Membrane
 liposomal model, cholesterol-dependent complement activation resulting in damage to, 342
 transport, in Con A-stimulated cells, 1328
 2-Mercaptoethanol, killer T cell induction, 1697
 Metiamide, neutrophil motility and, 1690
 Migration, *see also* Leukocyte migration inhibition
 eosinophil, histamine modulation, 137
 inhibitory factors
 chromatographic behavior, 2015
 histamine-induced suppressor factor effect on, 1734
 isoelectric points, 2015
 macrophage responsiveness to, 1
 production, stimulation by soluble tumor-associated antigen, 1244
 Microglobulin, B₂-IgG chain complex, 1962
 Microwave-induced increase in complement receptor-bearing lymphoid spleen cells, 1499
Mitogen, *see also* Receptor
 activation of chronic lymphatic leukemia cells, 742
 activity, of *Actinomyces viscosus*, 1435
B cell
 A. viscosus antigens as, 1460
 type C RNA virus induction, 662
 -induced peripheral blood lymphocyte proliferation, 1763, 1768
 lymphocyte response to, cytochalasin B effect on, 1472
 -stimulated lymphocytes, interferon production, 1366
 pokeweed, tonsil B cell responses to, 2009
 response
 Marek's disease-infected lymphocyte effect on, 887
 of human T cell subpopulations, 193
 polymixin B inhibition of, 21
 stimulation, lymphocyte proliferation in response to, 1966
 T cell, cross-linking, 863
 Mitogenesis, LPS-induced, unresponsiveness of C3H/HeJ mouse spleen cells to, 274
 Mitogenicity, lymphocyte, ionophores and, 129
 Mitomycin C-treated tumor cells, immunogenicity, 685
 Mixed leukocyte culture, *see also* Leukocyte culture
 cells, Con A induction of cytolytic activity, 35
 Mixed lymphocyte reaction
 abnormal mediator production in immunodeficiency disease, 858
 homologous erythrocytes of T cells in, 909
 inhibition with anti-Lyb-4.1 serum, 1143
 regulation by lymphocyte subpopulations, 1252
 secondary *in vitro*, 1232
 suppressor cells, 1886
 to TNP-modified syngeneic lymphocytes, H-2 homology requirements, 1420
 Molecular control of B cell triggering, 2199
Moloney sarcoma
 -bearing rats, immune complexes, 2269
 disaggregated regressing, cytotoxicity mediated by macrophages recovered from, 1574
 growth enhanced by p30, 371
 Monocyte functional properties, 187, 1712
 -lymphocyte interactions, of T cell subpopulations, 193
 macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells, 729
 peripheral blood, isolation and enumeration, 1409
 Murine leukemia virus, H-2 complex influence on susceptibility to, 1239
 Murine sarcoma virus-immune lymphocytes, MIF production from, 1244
 Myasthenia gravis, experimental autoimmune, cytophilic antibodies in, 17
Mycobacterium bovis, *see also* Bacillus Calmette-Guérin
 strain BCG, tumoricidal and chemotac-

- Mycobacterium bovis*—continued
 tic responses of macrophages after infection with, 2176
- Myelin basic protein, *see under* Protein
- Myelin, demyelination by activated lymphocytes in eye, 2094, 2103
- Myeloid cell line, lymphocyte cytotoxicity against, 355
- Myeloma
 experimental, hypogammaglobulinemia in, 1385
 multiple
 mitogen-induced cellular cytotoxicity, 947
 peripheral blood studies, 1864
 -specific antibodies, 2206
- Myoglobin, conformational integrity in Freund's adjuvant, 226
- Neisseria gonorrhoeae*
 lytic susceptibility, 1843
- Neoplasm, solid, inflammatory cells in, 1574
- Nephritis, interstitial, cell-mediated, 589
- Nervous system
 peripheral cell, differentiation antigen expressed by lung tumor, 826
 -specific cell surface antigens, NS-2, 551
- Neural membrane antigens, 1995
- Neuroblastoma cell, neural membrane antigens, 1995
- Neuroblastoma patient, Gm phenotypes in serum, 1083
- Neutropenia, induced by systemic infusion of chemotactic factors, 1586
- Neutrophil
 chemotactic factor, in DNCB-induced skin inflammatory lesions, 762
 immune-dependent phagocytosis, 1354
 in antiviral defense, 1957
 motility
 histamine and, 1690
 metiamide and, 1690
- Newcastle disease virus, complement inactivation of, 348
- Nippostrongylus brasiliensis*, IgE formation after infection, 1982
- Niridazole
 -induced immunosuppression in urine, 418
 suppression of EAE, 2151
- Nucleotide levels
 antigen and, 446
 histamine and, 1690
 metiamide and, 1690
- Oligomer, IgG
 binding to Fc receptor-bearing cells, 1338
 biologic activity, 1348
- Orchitis, experimental allergic, pathogenesis, 1774
- Otitis media, acute, immune response to, 248
- Pancreas, immunologic reactivity of uro-kallikrein with antiserum against, 667
- Panencephalitis, subacute sclerosing, measles virus-specific immunoglobulins in, 291, 296, 2254
- Papain digestion, Fc fragments from IgG2a by, 388
- Papovavirus-transformed cells, cell surface antigens on, 2295
- Paragloboside, antibody reaction to, 1415
- Paramyxovirus infected cells, lymphocytes and, 1132
- Peptide bonds, aspartylprolyl, hydrolysis at, 67
- Peritoneal cavity nonphagocytic adherent cell, 1362
- Peritoneal cell, *see under* Cell
- Peyer's patch lymphoid cells, 992
- Phagocyte, mononuclear, suppressor factor, 1385
- Phagocytosis, immune-dependent, by neutrophils, 1354
- Phaseolus vulgaris*, interaction with E-PHA and anti-thymocyte globulin, 2213
- Phosphorylcholine, anti-phosphorylcholine antibodies, 1987
- Phytohemagglutinin
 -activated T lymphocytes, E rosette formation, 2291
 cutaneous basophil response, 1564
 erythroagglutinating, interaction with *P. vulgaris*, 2213
 -sensitive lymphocytes in normal and leprosy blood, 242
 skin testing, elicitation of cutaneous basophil response with, 1063
 suppression of mitogen-induced lymphocyte proliferation, 1768
- Plaque-forming cell, *see under* Cell
- Plaque-forming response to SRBC, IRA, immunosuppressive activity effect on, 1228
- Plaque, herpes simplex, antibody elimination of, 2167
- Plasma cell, Ig heavy chains, 1682
- Plasma, seminal, immunosuppressive activity, 1704
- Plasmacytoma
 -induced immunosuppression, 702
 MOPC 315, inhibition by GVH reaction, 1441, 1449
 SAMM 368-A, secreting IgG2b- κ and IgA- κ , 1682
- Platelet
 accumulation at site of antigen-antibody-mediated injury, 1569
 release reaction, induced by immunologic stimuli, 514
 response to zymosan in C5 deficiency, 12
- Pneumococcal cell wall, activation of alternative pathway, 451
- Pneumococcal polysaccharide type III, antibody response to, 952
- Pokeweed mitogen, tonsil B cell responses to, 2009
- Polyanion-polycation interaction, complement activation by, 83
- Polycation-polyanion interaction, complement activation by, 83
- Polyglycerophosphate, antibody to, 1154
- Polymyxin B, inhibition of LPS mitogenesis, 21
- Polypeptide p30, Moloney sarcoma growth and, 371
- Polysaccharide, *see also* Pneumococcal polysaccharide, 2155
- Pregnancy, urine, immunoregulatory properties of fractions, 881
- Properdin, *see also* Complement activation
 isolation and characterization, 103
 precursor, reversible transition to active, 525
- Propionibacterium acnes*, effect on growth of *L. monocytogenes* and *T. pallidum*, 109
- Prostaglandin, splenic, antigen-induced changes, 446
- Protein, *see also* Fetoprotein
 A, inhibition of antibody-dependent cellular cytotoxicity, 981
 amyloid A
 amino acid sequence, 1113
 -related serum component, 229
 antigens, lipid-conjugated, immune response to, 957
 C-reactive
 complement activation by interaction of polyanions and polycations in presence of, 83
 isolation from liver and serum, 1086
 lipid A-associated, induction of phenotypic lymphocyte differentiation, 1910
 myelin basic, EAE active sites, 1280
 Proteolytic cleavage, recovery of soluble erythrocyte receptor from T lymphocyte surface by, 1138
- Radiosensitivity of T and B lymphocytes, 1191
- Reaction, *see under* specific type of reaction
- Reactivity
 immune, lymphocyte, sensitization effect on, 1379
 immunologic, lung, 146
- Reaginic antibody formation, *see under* Antibody
- Receptor
 -binding sites, on C3 and C3b, 2145
 C
 -bearing lymphoid spleen cells, microwave-induced increase, 1499
 on visceral epithelial cells of renal glomerulus, 869
 ontogeny of cells bearing, 612
 C2b, modulation of function by cytochalasin-sensitive structures, 1292
 C3, binding sites, 2145
 cell, IgE binding to, 749
 erythrocyte, soluble, recovery from T lymphocyte surface, 1138
 Fc
 -bearing cells, 612, 1338
 -bearing lymphocytes, 943, 2058
 cell membrane, 819
 column fractionation to separate B cells and lymphocytes using, 1919
 soluble IgG aggregate binding to, 514
 glucocorticoid, in peripheral blood lymphocytes, 1977
 IgG
 levamisole and, 1119
 of yolk sac membrane, 782
 IgM-coated erythrocytes, on chronic

- lymphatic leukemia cells, 1010
- mitogenic, on peripheral blood lymphocytes, 2213
- Reovirus-like agent in stools, detection, 1275
- Response, *see also* specific types of response
 - antibody
 - hapten-specific IgE, 48
 - in vitro*, from peripheral blood lymphocytes, 630
 - induction *in vitro*, 2034
 - regulation in different Ig classes, 840
 - to type III pneumococcal polysaccharide, 952
 - viral, among Amish families, 1659
 - blastogenic, to ecotropic C-type viral gp71, 928
 - chemotactic, of macrophages, 2176
 - cytotoxic
 - to ecotropic C-type viral gp71, 928
 - to minor histocompatibility antigens, 1370
 - humoral, to H-2 public specificity, genetic control, 1403
 - immune, *see also* Immunosuppression
 - C. parvum*-activated macrophage promotion of, 1530
 - carrageenan effect on, 1213
 - cell-mediated, 1095, 1886
 - in recovery from Sindbis virus encephalitis, 1070
 - leukemogenic potential and, 607
 - LPS-induced suppression, 789
 - lung, 1728
 - suppression by low density lipoprotein, 648
 - to acute otitis media, 248
 - to eye anterior chamber immunization, 809
 - to LDH-C₄, genetic control, 2293
 - to lipid-conjugated protein antigens, 957
 - to syngeneic lymphoma cells, 122, 1090
 - tumoricidal, of macrophages, 2176
- Rheumatic disease, anti-DNA antibodies in, 694
- Ribonucleic acid
 - tRNA-specific antibodies, 1016
 - type C virus induction, genetic control, 662
- Rosette
 - E
 - active, test, 62
 - formation by PHA-activated T lymphocytes, 2291
 - forming blasts, acute lymphoblastic leukemia antigens detected with antisera to, 309
 - formation, lymphocyte, augmentation by leukocyte dialysates, 1672
 - forming cells
 - mitogenic response, 193
 - monocyte-lymphocyte interactions, 193
- Rous sarcoma virus, tumor growth and antibodies after challenge with, 1541, 2237
- Sarcoma, *see also* specific types of sarcoma; Tumor
 - chemically induced, cross-reacting antigens in, 1590
- Schistosoma mansoni*
 - antibody-dependent eosinophil-mediated damage to, 2221, 2230
 - soluble egg antigens, partially purified, 373
- Schistosomiasis, morbidity to in athymic mice, 594
- Schwann cell, differentiation antigen expressed by lung tumor, 826
- Sendai virus-stimulated leukocytes, interferon production, 1931
- Sensitivity, *see also* Hypersensitivity, Hyposensitivity
 - contact, macrophage as stimulator cell, 1677
- Serum
 - albumin, DNP-substituted, interaction with C₁, 223
 - anti-Lyb-4.1, inhibition of mixed lymphocyte culture response, 1143
 - blocking factors, in patients with marrow grafts from HLA identical siblings, 1799
 - C-deficient, virus neutralization by, 28
 - C-reactive protein, 1086
 - Gm phenotypes in neuroblastoma patients, 1083
 - immunoregulatory factors isolated from, 505
- Sialic acid, type-specific polysaccharide, 2155
- Sindbis virus encephalitis, immune response in recovery, 1070
- Skin
 - allograft, cyclophosphamide effect on specific unresponsiveness to, 1456
 - bullous pemphigoid antigen isolation, 455
 - inflammatory lesions, DNCB-induced, neutrophil chemotactic factor in, 762
 - testing, PHA elicitation of cutaneous basophil response with, 1063
- Soluble egg antigen, partially purified, schistosomal, 373
- Spleen
 - cell
 - cytotoxicity, SV40 tumor-mediated suppression, 203
 - IgE antibody response induction, 840
 - lymphoid, complement receptor-bearing, 1499
 - mitogen response, Marek's disease-infected lymphocyte effect on, 887
 - polymyxin B inhibition of LPS mitogenesis in, 21
 - regulation of LPS-induced granulopoiesis, 1435
 - regulation of macrophage formation, 1435
 - suppression of HGG response, 1880
 - suppressor and helper cell activity enhancement, 151
 - TNP-modified, H-2 antigens on, 797, 803
 - unresponsiveness to LPS-induced mitogenesis, 274
 - cyclophosphamide-induced modifica-
- tions, 1595
- derived chemotactic factor in malaria, 478
- lymphocyte
 - immune competence after GVH disease, 657
 - reactivity against syngeneic UV-induced tumors, 1483
- prostaglandin, antigen-induced changes, 446
- Splenectomy, neonatal, autoantibody formation and, 1524
- Sporozoite-induced malaria, immunity to, 1322
- Staphylococcus aureus* protein A, inhibition of antibody-dependent cellular cytotoxicity, 981
- Stool, reovirus-like agent in, 1275
- Streptococcus
 - Group B
 - opsonophagocytic antibodies to, 673
 - type Ia polysaccharide antigens, 2155
 - Group C carbohydrate hapten, 6
- Strontium, radioactive, suppression of killer cell activity, 1503
- Suppressor cell, *see under* Cell
- Systemic lupus erythematosus, anti-DNA antibodies in, 694
- Tetanus-diphtheria toxoids, IgE antibody development after immunization with, 334
- Thymectomy, neonatal
 - autoantibody formation and, 1524
 - IgE proliferation and, 1982
- Thymidine transport in Con A-stimulated cells, 1328
- Thymocyte
 - alloantigen-stimulated, induction of cell-mediated cytotoxicity, 1129
 - anti-thymocyte globulin, interaction with E-PHA, 2213
 - Ia antigen on, 998
- Thymus
 - B lymphocyte colony-forming cells, 1208
 - dependency of eosinophilia, granuloma formation, and host morbidity to schistosomiasis, 594
 - dependent antigen, suppression of immune response to, 789
 - dependent interferon, 256
 - maturation, by secretory macrophage product, 1780
 - suppression of delayed hypersensitivity, 1665
- Tissue, *see under* specific types of tissue
- Tolerance
 - B cell, to dextran B1355, 1265
 - induction of bone marrow cells, 2111
 - to HGG, suppressor cells in, 2125
- Tonsil, B cell responses to pokeweed mitogen, 2009
- Toxoid, *see under* specific types of toxoid
- Transplantation, immunity to leukemia-associated antigens, H-2 restrictions, 1259
- Treponema pallidum*, *P. acnes* effect on growth, 109
- Trinitrophenyl
 - modified cell
 - glutaraldehyde effect on, 1755

Trinitrophenyl-modified cell—*continued*

H-2 antigens on, 797, 803

T cell-mediated cytotoxicity against, 1755

-modified lymphocyte, mixed lymphocyte reaction to, 1420

Trypsin, C3 fragmentation by, 2192

Tumor, *see also* Lymphoma

-associated antigen, soluble, MIF production stimulated by, 1244

-associated lymphoid cells, activity after administration of irradiated syngeneic and allogeneic tumor cells, 986

-bearing mice

macrophage function, 2176

suppressor cells, 412

T lymphocyte inhibitor in, 211

cell

cytotoxicity to in tissue culture, 1925

growth, *C. parvum*-activated macrophage suppression of, 1530

killing by antibody and complement, Con A effect on, 1626

mitomycin C-treated, immunogenicity, 685

growth

after RSV challenge, 1541

allogeneic effect, 1441, 1449

antibody-mediated suppression, 489, 494, 498

C. parvum-activated macrophage suppression of, 1530

T cell-mediated enhancement, 1517

immunity, systemic, passive transfer, 122

lung, differentiation antigen expressed by, 826

Rous sarcoma virus-induced, cellular anti-tumor immunity, 2237

-specific immunity, 971

SV40-mediated suppression of spleen cell cytotoxicity, 203

syngeneic, T and B lymphocyte migration into, 1042

UV-induced, splenic lymphocyte reactivity against, 1483

L-Tyrosine-*p*-azophenyltrimethylammonium, B cell expansion to, 1311

Udder, bovine, immune system, 461

Urine

HLA antigens, 264

niridazole-induced immunosuppression, 418

pregnancy, immunoregulatory proper-

ties of fractions, 881

Urokinase, immunologic reactivity, 667

Virus, *see also* Antibody, viral; specific types of virus

antiviral defense, neutrophils in, 1957

complement inactivation of, 348

ecotropic C-type gp71, blastogenic and cytotoxic responses to, 928

-induced lymphoma, immune response to, 122

MHV3, neonatal susceptibility to, 1219

neutralization by complement-deficient sera, 28

SV40-transformed cells, somatic cell hybrids with peritoneal macrophages, 1951

Xenoantibody, in humoral cytotoxicity testing, 1836

Xenogeneic reconstitution factor, 1129

Yolk sac membrane, IgG receptor, 782

Zymosan platelet responses to in C5 deficiency, 12

INTRODUCTORY PEROXIDASE KIT\$200.00

(\$269.00 value if components are individually ordered)

Lyophilized

5ml Peroxidase Conjugated Anti-Human IgG

5ml Peroxidase Conjugated Anti-Rabbit IgG

5ml Peroxidase Conjugated Anti-Goat IgG

1ml Anti-Peroxidase (Horseradish)

1ml Anti-Human IgG

1ml Anti-Rabbit IgG

1ml Anti-Goat IgG

0.5ml Peroxidase (Horseradish)

0.5ml Human IgG

0.5ml Rabbit IgG

0.5ml Goat IgG

ALL PEROXIDASE CONJUGATES ARE PRODUCED FROM
IgG FRACTIONS AND ARE CONCENTRATES.

Peroxidase Conjugates of F(ab')₂ Fragments of Antiserums
are Available upon Request.

Specialists in Fluorescein, Rhodamine, Ferritin and Peroxidase Conjugations and of
Conjugated F(ab')₂ Fragments or Fab Fragments of Antiserums



cappel laboratories, inc.


COCHRANVILLE, PA. 19330

(215) 593-6914

HETROL SLIDE TEST



SCREENS
AND
CONFIRMS
IN ONE
SIMPLE PROCEDURE



DETECTION OF INFECTIOUS MONONUCLEOSIS ANTIBODIES

Hetrol Slide Test screens and confirms in one simple operation, differentiating Infectious Mononucleosis from other heterophile antibodies.

A presumptive test and a confirming test performed on the same slide at the same time detect the presence of Infectious Mononucleosis antibodies.

Hetrol test cells are stabilized suspensions ready-for-use.

Hetrol Slide Test eliminates preparation of fresh erythrocytes, and is comparable in specificity with differential tube tests.

Infectious Mononucleosis positive and negative controls are included to insure reliable results.

Hetrol Reagents are stable when stored at 2-10° C.

Literature available on request.

DIFCO

DIFCO LABORATORIES Detroit Michigan USA